A mathematical analysis of the financial and medical impact of hepatitis C among drug users in Perth, Western Australia by Kirkpatrick, Raelene
Edith Cowan University 
Research Online 
Theses: Doctorates and Masters Theses 
1-1-2003 
A mathematical analysis of the financial and medical impact of 
hepatitis C among drug users in Perth, Western Australia 
Raelene Kirkpatrick 
Edith Cowan University 
Follow this and additional works at: https://ro.ecu.edu.au/theses 
 Part of the Health Economics Commons 
Recommended Citation 
Kirkpatrick, R. (2003). A mathematical analysis of the financial and medical impact of hepatitis C among 
drug users in Perth, Western Australia. https://ro.ecu.edu.au/theses/1332 
This Thesis is posted at Research Online. 
https://ro.ecu.edu.au/theses/1332 
Edith Cowan University 
  
Copyright Warning 
  
 
  
You may print or download ONE copy of this document for the purpose 
of your own research or study. 
 
The University does not authorize you to copy, communicate or 
otherwise make available electronically to any other person any 
copyright material contained on this site. 
 
You are reminded of the following: 
 
 Copyright owners are entitled to take legal action against persons 
who infringe their copyright. 
 
 A reproduction of material that is protected by copyright may be a 
copyright infringement. Where the reproduction of such material is 
done without attribution of authorship, with false attribution of 
authorship or the authorship is treated in a derogatory manner, 
this may be a breach of the author’s moral rights contained in Part 
IX of the Copyright Act 1968 (Cth). 
 
 Courts have the power to impose a wide range of civil and criminal 
sanctions for infringement of copyright, infringement of moral 
rights and other offences under the Copyright Act 1968 (Cth). 
Higher penalties may apply, and higher damages may be awarded, 
for offences and infringements involving the conversion of material 
into digital or electronic form.
USE OF THESIS 
 
 
The Use of Thesis statement is not included in this version of the thesis. 
A MATHEMATICAL ANALYSIS OF THE FINANCIAL AND 
MEDICAL IMP ACT OF HEPATITIS C AMONG DRUG 
USERS IN PERTH, WESTERN AUSTRALIA. 
R. Kirkpatrick B. A. (Ed) 
A research Project Submitted in Partial Fulfilment of the Requirements for the 
Award of 
Master of Science (Mathematics and Planning) 
At the Faculty of Computing, Health and Science at Edith Cowan University 
Date of Submission: 141h August 2003 
CONTENTS 
Abstract 
Declaration 
Acknowledgements 
CHAPTER 
I. 
2. 
3. 
4. 
BACKGROUND TO HEPATITIS C 
Pathophysiology 
Prevalence 
Treatment 
INJECI'ING DRUG USE: Transmission, Prevalence Rates and 
Practices 
Transmission Modes 
Prevalence Rates 
Incidence and Prognosis of cirrhosis and hepatocellular carcinoma 
Injecting Drug Use Practices 
Transmission through needle Rharing 
THE MATHEMATICAL MODEL 
Background to Mathematical Models 
Mathematical Models 
Numerical Approximation Techniques 
Computational Methods 
MODEL PARAMETERS 
Population Sizes 
Number oflVDU cirrhosis/HCC cases 
Number ofiVDU's with hepatitis C Infection 
Number ofiVDU's that do not have the hepatitis C virus 
Page I 
Page 
8 
9 
10 
II 
II 
16 
20 
25 
25 
26 
42 
42 
51 
54 
54 
60 
66 
68 
80 
80 
82 
82 
83 
Recruitment and Migration Rates 84 
Rate of Needle Sharing Per Unit Time 85 
Probability of Transmission During a Single Needle Sharing Act 85 
Death Rate Due to hepatocellular carcinoma/cirrhosis 85 
s. SIMULATION RESULTS 87 
Total Intravenous Drug Using Population, 14,700 87 
Total Intravenous Drug Using Population, 19,600 100 
6. TREATMENT COSTS 112 
Treatment Costs from other Research 112 
Treatment Costs in 20 years Time for hepatitis C in Western Australia 117 
7. CONCLUSION 126 
Limitations and possible improvements to the mathematical model. 128 
REFERENCES 131 
Page2 
TABLE OF TABLES Page 
Table I. Prevalence ofHCV types in different donor populations 16 
Table 2. Side effects of Interferon treatment. 23 
Table 3. Significant risk factcr associated with HCV transmission among 26 
blood donors {Ka\dor ct al. 1992). 
Table 4. Comparison of anti~HCV seropositive and seronegative groups. 27 
(Bell et al. 1990) 
Table 5. Percentage of injecting drug users seropositive for hepatitis C 27 
virus, by sex, age at interview and duration of injecting (Crofts ct 
at. 1993). 
Table 6. Percentage of male and female intravenous drug users who were 28 
HCV seropositive, and odds ratios for .seropositivity after adjusting 
for age and duration of injecting ((~rotls ct al. 1993). 
Table 7. Univariate analyses of I ICY prevalence among 20 I JDUs 30 
attending Kirkcton Road Centre (van Beck ct al. 1994). 
Table 8. Multivariate logi!ltic analyses of I ICY prevalence among IDUs 31 
attending Kirkcton Road Centre ( van Beck ct al. 1994). 
Table 9. HCV antibody prevalence in prison entrants in Victoria, Australia, 33 
according to usc ofinjL-cting drugs, October 1991 to September 
1992. (Croft, N ct al. 1995). 
Table 10. Incidence of infection with hepatitis C virus among subjects ]] 
entering prison more than once, October 1991 to September 1992. 
( Crofts, N et al 1995) 
Table II. Characteristics of IICV Positive Respondents (n=6) (Carruthers 35 
and Loxley, 1994) 
Table 12. HCV reactive serology by age, treatment, age/treatment, last drug 36 
injected and duration of injecting drug usc. (Bevan, Loxley and 
Carruthers, 1996). 
Table 13. Biennial incidence of hepatitis C virus in a cohort of Victorian 38 
injecting drug users, 1990-1995. (Crofts and Aitken, 1997). 
Table 14. Age-standardised hepatitis C prevalences and confidence intervals, 38 
by city and gender (Loxley et al, I ~97). 
Table 15. Self reported positive llepatitis C result by key variables for those 39 
Hepatitis C tested· Percent respondents. 
Table 16. Percentage of respondents po~itive for hepatitis C by length of use. 40 
(Lenton, S & Tan-Quiglcy, A 1997). 
Table 17. Mean age at first heroin usc for respondents born in different 40 
decades. (Lynskey and llall, 1998). 
Table 18. Number and rate of diagnosis of hepatitis C infections 1994-1998 41 
for Western Australia. (Annual Surveillance Report, 1999). 
Table 19. Number of diagnoses of hepatitis C infection, 1998, by age group 41 
PagcJ 
and sex (Annual Surveillance Report, 1999). 
Table20. Comparison of needle sharing practices in the 1989 and \990 43 
ANAIDUS studies (Ross, Stowe, Wodak and Gold 1993). 
Table 21. HRBS scores for injectors (ever injected) (n '·' 167} (Carruthers 44 
and Loxley, 1994). 
Table 22. Frequency and percentage of responses to questions comprising 46 
the HRBS Drug Uses sub Scale (Bevan, Loxley and Carruthers, 
1996). 
Table 23. Self-reported re-use and sharing of needles on the last injecting 47 
occasion for respondents who had injected in the last month 
(n~t94) (Bevan, Loxley and Carruthers, 1996). 
Table24. Risk management strategies for injecting: Injectors (n ~"' 79) 47 
(Carruthers and Loxley, \994). 
Table 25. Comparison ofiiRBS scores Fitpack vs Perth ASltiDU. (Lenton 49 
& Tan-Quiglcy, !997). 
Table 26. Times in past month respondent shared other injecting etluipment so 
(Lenton & Tan-Quigley, 1997). 
Table27. Rate of needle sharing by duration of usc and year ofiDUs 51 
accessing needle and exchange programs. ( 1999 Annual 
Surveillance Report). 
Table 28. llcpatitis C virus prevalence and incidence among 202 injecting 52 
drug users interview~.'-d thn~ times or more, by levels of risk, 
1990-1995 (Crofts and Aitken 1997). 
Table29. Seroconversion ha?.ard rates a~d means times to infection with 53 
HCV among injecting drug users in two independent studies in 
Victoria and Sydney (Crofts ct al 1997). 
Table 30. Number of persons in each age group by gender in 2001 Source 81 
for population data: Cdata200 1. 
Table 31. Estimated number of intravenous drug users in Western Australia 81 
by duration of usc. 
Table 32. Estimated number of intravenous drug users with cirrhosis/IICC 82 
by duration of use in 2001. 
Table 33. Estimated number of intravenous drug users mfcctcd with the 83 
hepatitis C virus by duration of usc in 2001. 
Table 34. Estimated number of intravenous drug users not infected with the 84 
hepatitis C virus by duration of usc in 2001. 
Table 35. Estimated number ofpc:-sons recruited to the IVDU per annum. 84 
Table 36 Rate of needle sharing per month 85 
Table 37. Parameters: Population 14,700, low infectivity rates and a low 88 
probability of infection from a single needle sharing act. 
Table 38. Number of susceptible, infectious and removals after 20 years with 90 
varying recruitment and migration rates. 
Table 39. Number of susceptible, infectious and removals after 20 years with 93 
Page4 
varying recruitment and migration rates. 
Table 40, Parameters: Population 14,700 with high infectivity rates and a 94 
low probability of infection from a Hingle needle sharing act. 
TablC' 41. Number of susceptible, infectious and removals after 20 years with 96 
varying recruitment and migration rates. 
Table 42. Number of susceptible, inf<.'\:tious and removals after 20 years with 99 
varying recruitment and migration rates 
Table 43. Parameters: Population 19,600 with low inft-ctivity rates and a low 100 
probability of infection from a ~inglc nt-cdlc sharing act. 
Table 44. Number of susceptible, infectious and removals after 20 years with 102 
varying recruitment and migration rates 
Table 45. Number of susceptible, inft-ctious and n.:movals after 20 years with 105 
varying recruitment and migration rates. 
Table 46. Parameters: Population 19,600 with high infectivity rates and a 106 
low probability ofinft-ctinn from a single needle sharing act. 
Table 47. Number of susceptible, inft-ctious and removals after 20 years with 108 
varying rt-cruitmcnt and migration rates. 
Table 48. Number of susceptible, infectious and removals aller 20 years with 110 
varying recruitment and migration rates. 
Table 49. Divisi('ll into disease stages of the Sheil! ( 1999) cohort. 116 
Table SO. Cost of medical care, per individual, for the She ill ( \999) cohort. 117 
Table 51. Undiscountcd medical costs of hepatic disease in 20 years, using 118 
inflationa1y rates of I%, 2~'0 and 3%_ 
Table 52. Discounted medical costs of hepatic disease in 20 years, using 119 
inflationary rates of I%, 2% and J%. 
Table 53. Division into disease stages fnr best and worst case scenario from 120 
simulation. 
Table 54. Costs for medical care for best case scenario for population 121 
14.700. 
Table 55. Costs for medical care for worst case scenario for population 122 
14,700. 
Table 56. Costs for medical care for best case scenario for population 123 
19,600. 
Table 57. Costs for medical care for worsts! case scenario for population 124 
19,600. 
Page 5 
TABLE OF FIGURES Page 
Figure 1. Progression of liver cell failure. Pathophysiology of symptoms that 13 
occur in liver disease. 
Figure 2. The outcome of hepatitis C virus exposure. 15 
Figure 3. Transmission modes of hepatitis C, adapted from Mnddrcy ( 1994) 19 
Figurc4. Lack of accuracy of Euler's Method. 67 
Figure 5. Population of Western Australia in 2003 by age group and gender. SO 
Source: Cdata200\ 
Figure 6. Number of susccptibles after 20 years, population 14,700, low 88 
infectivity rates and a low probability of infection from a single 
needle sharing act 
Figure 7. Number of infectious after 20 years, population 14,700,\ow 89 
infectivity rates and a low probability of infection from a single 
O(..'Cd\c sharing act. 
Figure 8. Number ofrcnmvals after 20 years, population 14,700,1ow 90 
infectivity rates and a low pmbability of infection from a single 
needle sharing act. 
Figure 9. Number ofsusccptibles after 20 years, population 14,700, low 91 
infectivity rates and a high probability of infection from a single 
needle sharing act. 
Figure 10. Number ofinfcctiom after 20 years, population 14,700, low 92 
infectivity rates and a high probability ofinfection from a single 
needle sharing act. 
Figure 1 I. Number of removals after 20 years, population 14,700, low 92 
infectivity rates and a high probability of infection from a single 
needle sharing act. 
Figure 12. Number of susceptibles after 20 years, population 14,700, high 94 
infectivity rates and a low probability of infection from a single 
needle sharing act. 
Figure 13. Number of infectious after 20 years, population 14,700, high 95 
infectivity rates and a low probability of infection from a single 
needle sharing act. 
Figure 14. Number of removals after 20 years, population 14,700, high 96 
infectivity rates and a low probability of infection from a single 
needle sharing act. 
Figure 15. Number ofsusccptiblcs after 20 years, population 14,700, high 97 
infectivity rates and a high probability of infection from a single 
needle sharing act. 
Figure 16. Number ofinfcctious after 20 years, population 14,700, high 98 
infectivity rates and a high probability of infection from a single 
needle sharing act. 
Page6 
Figure 17. Number of su·~,:Cptibles after 20 years, population 14,700, high 98 
infectivity rates and a high probability of infection from a single 
needle sharing act. 
figure 18. Number of susceptibles after 20 years, population 19,600, low 101 
infectivity rates and a low probability of infection from a single 
needle sharing act. 
Figure 19. Number of infectious after 20 years, population 19,600, low 101 
infectivity rates and a low probability of infection from a single 
needle sharing act. 
Figure 20. Number of removals after 20 years, population 19,600,Iow 102 
infectivity rates and a low probability of infection from a single 
needle sharing act. 
Figure 21. Number of susceptible~ c.uer 20 years, population 19,600, low 103 
infectivity rates and a high probability of infection from a single 
needle sharing act. 
Figure 22. Number of infectious after 20 years, population 19,600, low 104 
infectivity rates and a high probability of infection from a single 
needle sharing act 
Figure 23. Number of removals after 20 years, population 19,600, low 104 
infectivity rates and a high probability of infection from a single 
needle sharing act. 
Figure 24. Number of susceptibles after 20 years, population 19,600, high 106 
infectivity rates and a low probability of infection from a single 
needle sharing act. 
Figure 25. Number of infectious after 20 years, population \9,600, high 107 
infectivity rates and a low probability of infection from a single 
needle sharing act. 
Figure 26. Number of removals after 20 years, population l'.l,600, high 107 
infectivity rates and a low probability ofinfcction from a single 
needle sharing act. 
Figure 27. Number of susccptibles afier 20 years, population 19,600, high 109 
infectivity rates and a high probability of infection from a single 
needle sharing act. 
Figure 28. Number of infectious after 2C years, population 19,600, high 109 
infectivity rates and a high probability of infection from a single 
nfedle sharing act. 
Figure 29. Number of removals after 20 years, population 19,600, high 110 
infectivity ra~es and a high probability of infection from a single 
needle sharing act. 
Page7 
ABSTRACT 
The ability of public health planners continues to be hampered by uncertainties 
encountered with transmissible diseases. Key epidemiological factors such as, how 
many Western Australian injecting drug USI~rs are hepatitis C seropositive or will become 
infected, duration of intravenous drug use, the intensity of infection, the fraction of those 
infected tbat will develop end~stage disease and after how long a period, all combine to 
limit the ability of a mathematical model to predict future trends. 
These models can, however, provide information about certain epidemiological 
parameters and identify data required to predict future trends. They can be applied to 
make predictions about the course of infection in the individual and provide a guide to 
the interpretation of the observed data. This research aims to develop a model of the 
transmission and spread of hepatitis C, adapting existing models used to predict the 
spread ofHIV and AIDS in one and two sex communities. This model will be used to 
demonstrate the dynamics and incidence of hepatitis C infection among injecting drug 
users in Perth, Western Australia. 
Predictions derived from the model will then be used to undertake an analysis of the cost 
of treating those with hepatitis C and cirrhosis related complications, resulting in a 
prediction of the financial impact of hepatitis Con the Western Australian community. 
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BACKGROUND TO HEPATITIS C 
1.1 Pathophysiology. 
The liver is an essential component in the maintenance of life. Not only does it rank first 
in actual mass, but first in the variety, range and complexity of its functions. It is 
involved in almost every metabolic function of the body, but is individually responsible 
for more than 500 separate functions (Price & Wilson, 1982). 
Major functions essential fur sustaining life include; the formation and excretion ofbile, 
carbohydrate metabolism, protein metabolism, fat metabolism, vitamin and mineral 
storage, detoxification, and a flood and filter mechanism. Total destruction or removal of 
the liver results in death within ten hours. 
Not only is the liver remarkable for the range of essential functions that it performs, it 
also possesses a phenomenal regenerative capability. Under normal circumstances only 
10-20% of liver tissue needs to be functioning optimally to sustain life. Regeneration of 
liver tissue remains possible, following assault or disease, when up to 500/o of hepatic 
cells have been damaged or destroyed (Price & Wilson. 1982). 
1.1.1 hepatitis C. 
In broad tenns, hepatitis describes the inflammation of the cells of the liver, where the 
causative agents include drugs, toxic materials, malignant diseases, alcohol, and micro-
organisms, including Epstein-Barr virus, Cytomegalovirus and hepatitis viruses (eg 
hepatitis A, hepatitis B) (Griffiths·Jones, A 1994). 
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The hepatitis C virus (HCV) was isolated in 1988 (Choo et.al1990). Previous to this, all 
cases of hepatitis not found to be caused by any of the above agents, were listed as 
hepatitis non-A, non-B. Since its isolation, two other causative viruses in the non-A, 
non-B hepatitis category have been identified, hepatitis D and hepatitis E. Of the three 
subgroups, hepatitis C is responsible for the majority of blood-borne non-A. non-B 
hepatitis cases (Lisanti, P. & Talotta, D. 1994). 
Hepatitis Cis a single-stranded RNA virus that can be further subdivided into distinct 
isolates or genotypes. A universal classification system for these genotypes established 
six major phylum. typesl to 6 where each have several closely related subgroups (ie a to 
c) ~Omish, F. et al. 1994). Investigations into a group of false-negative pathology 
tests among Asian sufferers has lead to the identification of further genotypes, 7, 8 and 9 
in Thailand, and types 10 and 11 among Indonesians. 
1.1.2 Clinical presentation. 
As with all hepatitis viruses, clinical presentation may at best be vague. As many as SO% 
ofpeop1e with hepatitis C may be completely asymptomatic (Steven, I. D. et al1994), 
and those that do present with symptoms will usually report feelings of tiredness, 
anorexia, muscle pain, and occasionally right abdominal pain (Griffiths-Janes, A 1994). 
While presenting symptoms are either mild or undetectable, at least half the adults with 
the disease progress to chronic, persistent infection (Hantz, 0. et al 1993). In many 
cases, chronic hepatitis C causes slow, insidious damage to liver cells that often leads 
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to cirrhosis and hepatocellular carcinoma decades after the initial infection (Hantz, 0. et 
all993). 
Liver damage, cause by invasion and replication of the virus, consists of inflammation 
and mononuclear celt infiltration. This occurs in the portal ducts and the parenchyma 
leading to hepatic cell necrosis. There is a corresponding increase in the size and number 
ofKupffer cells responsible for the phagocytosis of bacteria and otljer foreign particles in 
the blood. Cellular collapse and necrosis is the end result. The accumulation of necrotic 
tissue in the lobules and ducts of the liver lead to changes in its structure. This change in 
structure affects all liver functions (Lisanti, P. & Talotta, D. 1994). The progression of 
these changes to liver functions can be seen on the diagram below, modified from 
Phipp•, Long and Woods (1979). 
rnriL}ivV.c;;,J;inflOfiaamffinmaiiitiil· oiini1, 1r---,-1 ------ Gastrointestinal symptoms J nausea, vomiting 
I I Liver Necrosis 
I 
Increased Portal pressure 
Increased J.nous preF.run: 
I 
Pain _________ anorexia 
weight loss 
fatigue 
Decreased metabolism l Decreased bilirubin metabolism 
C.. Decrease hormonal metabolism 
i"('Tf.o;i;taJdiLI,iv;;;";-FF.ai!iii· illurorojf------- Hepatic Encephalopathy 
HLticcoma 
I 
O.a!h 
Figure 1. Progression of liver cell failure. Pathophysiology of symptoms that occur 
in liver disease. 
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1.1.3 Diagnosis. 
Diagnosis is possible through the detection of antibodies by enzyme immunoassay. 
There is, however a window periodof14 -180 days (Lisanti, P. & Talotta, D. 1994), 
before antibodies appear. The presence of hepatitis C antibodies indicates exposure to 
the disease only. Fa1se positive results occasionally appear, however diagnosis can be 
further verified using ELISA (enzyme-linked immunosorbent assay) (M"'Omish, F. et al. 
1994). This assay detects antibodies to specific viral proteins. PCR (polymerase chain 
reaction) another confirmatory test, investigates the presence of genomic material 
(RNA). There has been increased refinement in testing procedures in the period 1994 -
1996, leading to detection of the virus within 14 days of exposure and higher specificity 
and sensitivity. A negative result, however, does not indicate an absence ofHCV, as 
some people(- 4%, Nakagiri et al, 1993), are only intermittently antibody positive 
(Steven, I.D. et al 1994). 
1 .1.4 Prognosis. 
Cirrhosis of the liver, an end stage complication of chronic hepatitis C, is characterised 
by large and small degenerative nodules that are encased in scar tissue. Interspersed with 
these are nonnal liver parenchyma. Approximately 75% of cases of cirrhosis prove fatal 
within 1 - 5 years (Price & Wilson, 1982). Pathological changes progress slowly with 
only minor clinical symptoms until the major and late manifestations of the disease 
develop. These include: jaundice, peripheral oedema, bleeding disorders, hepatic 
encephalopathy, splenomegaly and oesophageal and gastric varices (Price & Wilson, 
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1982). In all cases, these symptoms are life threatening and can only be treated 
palliatively, at great expense to the community. There is no treatment to reverse the 
development of the fibrotic nodules, other than liver transplantation. 
Hepatitis Cis also closely linked with the development ofhepatoc.e1lular carcinoma. 
While hepatitis C has not been proven to be directly carcinogenic, studies indicate that 
there is significant malignant transformation in the form of chronic necroinflammatory 
hepatic disease, (as in the case of cirrhosis), that leads to the fonnation of carcinogenic 
tumours (Kew, M.C. 1994). Cancerous cells tend to compress the surrounding nonnal 
liver tissue and spread quickly via invasion oft he portal vein. Haemorrhage and cell 
destruction are major complications of hepatic carcinoma. Otherwise, progression of the 
disease may be asymptomatic. 
I warson describes the outcomes of exposure to Hepatitis C in the following diagram; 
Acute hepatitis 
(15-20%) 
Hepatitis C virus exposure 
Subclinical hepatitis 
(80-85%) 
Resolving Otronic 
liver disease 
(70-80'/co) 
Resolving Chronic 
liver disease 
(70-80%) 
Figure 2. The outcome of hepatitis C virus e~:posure. 
Page 15 
1.2 Prevalence. 
1.2. 1 Geographical distribution. 
As stated previously. hepatitis C has eleven distinct genomic types known to date. These 
are Types 1 to 11 with subgroups a, b, and c. The eleven major genomes have discrete 
nucleotide sequences in the 5'-Non-Coding Region of the virus (McOmish, F. et a1. 
1994), that a11ow identification from DNA amplification and PCR testing. Improvements 
in testing procedures has greatly increased the ability to reliably differentiate, using 
standard tests, between the subgroups of each genomic type. As the virus continues to 
evolve, it is possible more genotypes will be identified. 
In a study undertaken by McOmish and colleagues, 1994, 447 samples from nine 
different countries were examined, in an attempt to plot the global distribution of 
different genome groups. The participating countries were: Scotland, Finland, The 
Netherlands, Australia (Perth), Egypt, Hungary, Japan, Taiwan and Hong Kong. The 
table below shows the results of the investigation. 
Country No. of Number & percent of donor saml!les of IICV geno!J::~e 
Sam les" I 2 3 4 5 6 
Scotland 144 67 (47%) 21 (14%) 56 (39"/o) 0 0 () 
Australia 24 12(50%) 3 (13%) 8 (33%) 0 I (4%) 0 
Finland 12 3 (25%) 5 (42%) 4 (33%) 0 () 0 
The Netherlands 31 18 (58%,) 7 (23%) 5 (16%) 1 (3%) 0 0 
Hungary 47 46 (98%) 0 () I (2%) 0 0 
Egypt 19' 0 0 0 17(90%) 0 0 
Taiwan 93 53 (57%) 40 (43%) 0 0 0 0 
Japan 40 31 (77%) 9 (23%) 0 0 0 0 
Hong Kong 37" 22 {59'%) 1(3%) 0 0 0 12(32%) 
Total 447 252 86 73 19 I 12 
Table 1. Prevalence of HCV types in different donor populations 
• Number of PCR-posilivc samples typed by Restriction Fragment Length Pol)morphism (RFLP) 
h Two donors were infected with variants that cou1d not be classified as type Ito 6 
c Two donors showed evidence of mixed infection with types I and 6 
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Table 1 illustrates that the predominant genotype in Perth, Western Australia is type I, 
comprising 50% of the samples tested. Proportional incidence of types 2 and 3 are 13% 
and 33% respectively. The significance of the proportions of the genotype mix will be 
dealt with when discussing treatment of hepatitis C. 
A study by Lin et. al., (1996), investigated response rates to a~ Interferon among two 
hundred and thirty hepatitis C sufferers. This study represents one of the first studies to 
investigate genotype spread in Australia. Thirty.two ofsixty·fivc subjects were previous 
injecting drug users. Other transmission factors included occupational exposure (3%, 
n=2), blood transfusion (32%, n=21) and unidentified exposure ( 16%, n=\Gi. Twenty~ 
four subjects were found to have type 1 hepatitis C, 38 type 3 and 3 were fcund to have 
mixed type 1 and 3 hepatitis C. 
1.2.2 Transmission. 
While the major transmission mode for hepatitis Cis parenteral in up to half the reponed 
cases the mode of transmission remains unknown (Maddrey, W.C. 1994). Thus, 
intravenous drug users and recipients of blood transfusions, prior to 1990, comprise the 
two major known risk groups. Smaller risk !:,'TOups include male homosexuals and sex 
industry workers (Steven, I. D. ct a\1994). Injecting drug users comprise the major li~.K 
group. A number of surveys have established the prevalence ofHCV among intravenous 
drug users to be higher than 70% (Van Beck, I. et al_ 1994). Some studies have found 
infection rates of 100%. Current data suggests the modal infection route comes from the 
sharing of injecting equipment (Steven, l.D. et al 1994). 
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Transmission of hepatitis C via blood transfusions was a primary source of infection, 
prior to the development of accurate screening techniques in 1990. Due to the mildness 
of specific presenting symptoms, and the high percentage of asymptomatic carriers, the 
true number of those infected with hepatitis C from blood transfusions did not become 
apparent until afier 1988. The Centre for Diseuse Control (USA) now estimates 150,000 
or more acute 1-ICV infections each year (Maddrey. W .C. 1994). The rate of infection via 
blood transfusion has declined since 1990, as blood products undergo heat treatment to 
destroy the virus. Prothrombin (a clotting factor) is unable to undergo this preventive 
measure, (Steven, LD. ct al1994), which still leaves llaemophiliacs at risk of infection. 
By 2002, the Australian Red Cross Blood Service estimated the risk of contracting 
hepatitis C via a transfusion as I in 330,000 units transfused. 
There have been some studies that support the significance of sexual transmission of the 
virus (Gabrielli, C et al. 1994, Sato, B., ct a\ 1994). The establishment of a proportional 
rate of infection has not been established, but is thought to be in the region of 5% 
(Maddrey, W.C. 1994). Coupled with the sexual mode of transmission is evidence of a 
higher rate of transmission among those already infected with either the hepatitis B 
and/or HIV/AIDS virus (Gabrielli, C ct al. 1994, Sato. B., ct al 1994, Van Beck, I. et aJ. 
1994) with those working in the sex industry without adequate protection most likely to 
acquire the virus through sexual transmission (Nakashima, K., ct. al 1992). The pie chart 
below, adapted from Maddrey 1994, illustrates transmission modes of the hepatitis C 
virus. 
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Transmission of Hepatitis C 
Source 
Unknown 
43'1(, 
IOU 
40% 
Occupational Blood Tranfusion 
2'I(, Sexual Contact 1 ()'I(, 
5% 
Figure 3. Transmission modes of hepatitis C, adapted from Maddrey (1994) 
There are three other minor methods of contracting the hepatitis C virus. Organ 
transplant recipients are at risk. However, all donors are screened for HCV and the risk 
is minimal. Foetal infection has not been substantiated, although there does appear to be 
a higher incidence among mothers that are both HIV and HCV antibody positive. Health 
care workers are another group of people that are at risk of exposure, primarily through 
needle-stick injury. The rate of infection is lower with hepatitis C than with hepatitis B, 
and is estimated to represent 2-3% of the total population of those infected (Steven, 1.D. 
et al 1994). 
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1.3 Treatment 
1.3.1 Alpha-2b-lntcrfcron 
Interferons arc a group of low-molecular weight proteins produced by leukocytes 
(interferon alpha), fibroblasts (interferon beta), and T-lymphocytcs (interferon gamma) 
(Zein, N. N & Rake Ia, J. 1995). These proteins occurring naturally in humans have an 
anti-viral effect, utilised by a variety of mechanisms. These include the inhibition of 
viral replication, inhibition of viral protein production and the prevention of virions 
release from infected cells (Zein, N.N & Rakcla, J. 1995). Jlighly purified interferons 
we!c made available for public consumption following the introduction of recombinant 
DNA technology. 
There are three commercially available types of interferons. Two of them are 
recombinant interferons, interferon alpha-2a and interferon alpha-2b, while the third is a 
naturally occurring interferon, interferon alpha-NL (Zein, N.N & Rakela, J. 1995). 
Due to the high percentage of people with an absence of clinical signs it is often difficult 
to institute a-Interferon therapy in the early stages of the disease. Where inflammation 
of the liver is detected, it is recommended that treatment begin. Those patients with 
advanced cirrhosis and major neuropsychological symptoms are not appropriate 
candidates for a-interferon therapy (Maddrey, W.C. 1994). 
Treatment of acute-phase hepatitis C infection with a-interferon has produced initial 
evidence that it may prevent progression to chronic hepatitis C. It must be 
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emphasised that this evidence is not conclusive due to small sample sizes and the varying 
dosages used in each study (Zein, N.N & Rakela. J. !995). 
Alpha-interferon is the medication of choice in the treatment of chronic hepatitis C. The 
generally accepted regime involves the administration ofJ million units, by injl.-ction, 
three times a week for twenty-four weeks (Hantz, 0., Turin, F. and Trepo, C. 1993, 
Maddrey, W.C. 1994, SchilT, E.R. 1993, Zein, N.N & Rakela, J. 1995). Studies have 
shown that only 50% of those treated respond, with a return to normal alanine 
aminotransferase treatment (ALT) levels, after six months of therapy. Only 25% of these 
maintain a sustained recovery (Maddrey, W.C. 1994, Zein, N.N & Rakela, J. 1995), with 
females and younger perso:1s experiencing better responses to treatment. The reasons 
why a sustained response is not maintained arc not completely clear, although factors that 
influence the response to interferon therapy have been identified. 
a) Age and gender: A study by Causse et al, demonstrated an independent positive 
correlation with female sex (P<0.03) and younger age (P<O.OS) (Zein, N.N & Rakela, J. 
1995). Hantz, Turin and Trepo (1993) also indicate younger age as an indicator for 
enhanced response to interferon therapy. 
b) Dosage and duration of therapy: Studies arc still progressing in an effort to identify a 
regime that will produce maximum benefit, combined with minimum side effects. 
Currently optimal dosage and duration of therapy have not been established, and a more 
effective regime than 3 million units, three times a week, for twenty-four weeks, may be 
identified. 
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c) Type of interferon: There has been very little investigation into the effectiveness of the 
different types ofinterferons available. A study by C. Cimino et al, (1992, cited in Zein 
et al, 1995), identified ten patients who, after not responding to the recommended 
treatment with interferon alpha-2a. were then treated with lymphoblastoid interferon 6 
million units, three times a week for 2 months, followed by a reduction to 3 million units, 
three times a week for 4 months. Five of the recipients showed a return to nonnal AL T 
levels at the end of the treatment (Zein, N.N & Rakela, J. 1995). 
d) Liver Histology: Biopsy of the liver, prior to interferon therapy, allows a precise 
measurement of the progression of chronicity. As the disease proceeds healthy liver 
tissue is replaced with scarred and fibrotic tissue. Studies have shown that patients with 
little or no fibrosis responded to therapy significantly better than those with severe 
hepatic disease. A summary of these studies shows that the rate of sustained response to 
therapy is greater in those patients with only mild hepatitis compared to those with active 
disease, evidenced by fibrosis or cirrhosis. Those with cirrhosis have the least likely 
response to interferon treatment (Zein, N.N & Rakela, J. 1995). 
e) Serum HCV RNA level: Blood sampling to measure the level of hepatitis C virus 
RNA levels prior to the commencement ofintetferon therapy, appears to be a useful 
predictor of responsiveness to the treatment. Those people with significantly lower titre 
levels were more likely to be long-term responders. It is interesting to note that in a 
study by Hagiwara and associates, higher titre levels corresponded with those patients 
with advanced liver disease, following biopsy (Zein, N.N & Rakela, J. 1995). 
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f) HCV genotype: Studies have shown that partial or complete short-term biochemical 
response to interferon was demonstrated in 55% of patients with HCV type 1 b, whereas., 
an 89"/o response rate was identified with patients of other types, primarily type 2a, 2b 
and type 3. A statistica11y significant difference ofp---Q.Ol was demonstrated. These 
studies however are still preliminary, and there is some conjecture that mutation of the 
viral RNA is the cause of resistance to therapy (Zein. N.N & Rakela, J. 1995). 
A list of the side effects of interferon therapy are listed below along with the percentage 
of patients experiencing them. (Zein, N.N & Rakela. J. 1995). It should be noted that 
some of the side effect are quite severe and may require extreme and long term medical 
support in their own right. 
Side effl;Ci.s 
Flu-like syndrome 
Fever, headache, chills, myalgia, fatigue 
Bone marrow hypoplasia 
Anaemia, leucopoenia, thrombocytopenia 
Cardiovascular disorders 
Arrhythmia, cardiomyopathy, hypertension 
Endocrine disorders 
Exacerbation of diabetes mellitus, thyroid, gynecomastia 
Gastrointestinal disorders 
Taste a1teration, anorexia, diarrhoea 
Liver and biliary 
Jaundice, autoimmune hepatitis, hepatic failure/ 
encephala ath 
Table 2. Side effeds of Interferon treatment. 
Percent of 
Patients(%) 
60-80 
<5 
<5 
<5 
15-25 
<5 
Two other problems exist with therapy involving interferons. The treatment is very 
expensive, ranging from $33,000 to $70,000 per course of treatment, dependent on the 
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severity of the disease at the commencement of treatment (Sheill, A. et al 1994). 
Finally, interferon must be administered subcutaneously. In most cases this involves 
visiting the doctor or hospital three times a week. causing inconvenience and added cost. 
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INJECTING DRUG USE: TRANSMISSION, PREVALENCE RATES 
AND PRACTICES. 
This chapter undertakes a full review of Australian studies examining transmission 
modes, prevalence rates and injecting drug use practices o( intravenous drug users. The 
review is undertaken in chronological order. 
2.1 Transmission Modes. 
Intravenous drug users (IVDU's) comprise the major population group at risk of 
contracting hepatitis C (HCV). Transmission occurs primarily through the sharing of 
needles and injecting equipment, including spoons, filters and water. Studies conducted 
in Australia have shown transmission rates among injecting drug users to be dependent 
on duration ofinjecting drug use, age and frequency of needle sharing. To a lesser extent 
opiate users are more likely than stimulant injectors to have contracted the virus as are 
those previously exposed to hepatitis B and heterosexual IVDU' s rather than homoser.uai 
IVDU's (van Beek eta!. 1994). 
Kaldor et al, (1992) estimated risk factors for hepatitis C from a cohort of blood donors 
in Sydney over a fourteen month period. Injecting drug use was identified as the major 
risk factor in 47.7% ofHCV infections. with a relative risk (estimated as an odds ratio) 
of 63 (95% confidence interval, 19-260). Other significant transmission faetors include 
tattoos (40%), more than one lifetime sexual partner (9.1%), a previous sexually 
transmitted disease (30%) and time spent in prison (12.3%). The authors discuss the 
limits associated with their findings, including a self-report method that may have 
introduced bias, but many of their findings have been supported elsewhere (Waddell, 
R.G. 1994; van Beek eta!. 1994; Croft, Net a!. 1993; Crofts N. eta!. 1995). Table 3 
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shows the significant risk factors associated with HCV transmission identified in this 
study. 
Risk Factor 
Injecting Drug Use 
Tattoo 
More than one 
lifetime sexual partner 
Sexually transmissible 
disease+ 
Hepatitis-like 
symptoms 
Hepatitis contacts 1 + 
Prison inmate 
Institution resident+++ 
Cases(%) 
responding 
yes to 
surve 
105(47.7%) 
67(30.4%) 
88(40.0%) 
66(30.0%) 
36(16.4%) 
56(25.4%) 
27(12.3%) 
38(17.3%) 
Relative Risk 2-tailcd P 
(95% confidence value 
lnterval) 
63(19-260) <0.00001 
11(4.9-26) <0.·00001 
7.2(4.1-\3) <0.0001 
4.6(2.5-8.4) <0 •JOOI 
4. 9(2.1-12) <! iJOOl 
2.1(1.3-3.6) 0.(1024 
14(3.3-91) <0.0001 
2.9(1.4-4.6) O.OC075 
Table 3. Significant risk factor associated with HCV transmission among blood 
donors (Kaldor et al. 1992). 
• items not mutuWJy exclll:livc 
+Syphilis, gonorrhoea, genital hcrpc:s, gcnilal wmts. non-specific urd.britis. 
++Sexual or familial contact with a person who twd hepatitis 
+t+ Anncd forces, hospital, boarding school, children's home 
2.2 Prevalence Rates. 
One of the earliest studies on the prevalence of hepatitis C among Australiar1 intravenous 
drug users was undertaken by Bell and associates in 1990. At a time wh!n diagnostic 
testing of hepatitis C was in its infancy, 172 intravenous drug users had their blood tested 
for HCV antibodies comparing prevalence rates against duration of drug usc. Infectivity 
increased markedly i~!'-length of drug used increased (see Table 4). 
Bell et al. ooncludcd that the odds of being HCV seronegative decreased by a 
multiplicative factor of 0.55 (95%C.I. 0.32 to 0.96) for each additional two years of 
intravenous drug use. 
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Anti-HCV 
status 
Men Wome 
(n) n (n) 
Total 
(o) 
Age 
(years) 
Duration of injecting 
drug use (months) 
Seropositive 
Seronegative 
99 49 
13 Jl 
148 
24 
25.6±4.0 
24.9±5.1 
63±36 
37±25 
Table 4. Comparison of anti~HCV seropositive and seronegative groups. (Bell et al, 
1990) 
Desland and Batey (1991) reported mean ages of first injecting from two study groups in 
Sydney. New South Wales. Participants recruited from a Court Diversion pmgram 
reported a mean age of first injecting of 14.0 years (SD 3.7 years) while those from a 
self-referred group had a mean age of 16.3 years (SD 4.7 years). 
In a study of injecting drug users in Victoria (Crofts et al. 1993), 303 men and women 
were tested for the presence of HCV antibodies. Results for those testing positive are 
given as; a} duration of injecting drug use by age at interview (Table 5) and b) an odds 
ratio model after adjusting for age and duration of injecting (Table 6). 
Duration of Percentage of injecting drug users (n) 
injecting <25 years 25-29 311-34 35+ years Total 
~ears ;rears ~ears 
Men 
0-4 37%(38) 25%(8) 67%(3) 0(2) 37%(51) 
5-9 67%(18) 63%(19) 67%(9) 100%(2) 67%(48) 
10-14 100"/o(17) 93%(14) 100%(8) 90"/o(39) 
15+ 100%(45) 100%(16) 90%(28) 93%(45) 
Total 46%(56) 64%(45) 88%(42) 90%(40) 70%(183) 
Women 
0-4 35%(40) 60%(5) 0(4) 100%(1) 40%(50) 
5-9 75%(16) 70%(10) 100"/o(2) 100"/o(3) 77%(31) 
10-14 100%(12) 83%(6) 67%(3) 90%(21) 
15+ 100%(1) 70%(10) 100"/o(7) 83%(18) 
Total 46%(56) 82%(28) 73%(22) 93%(14) 65%(120) 
Total 46%(112) 71%(73) 83%(64) 91%(54) 68%(303) 
Table 5. Percentage of injecting drug users seropositive for hepatitis C virus, by 
sex, age at interview and duration of injecting (Crofts et al. 1993). 
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Variable Number Odds ratio 9S%CI 
(!QSitive {%~ 
Men(n-183} 
Sexual orientation 
Heterosexual 157(69%) 1.0 
Bi/Homose:rrual 21{59%) 0.62 0.2-1.8 
Current primary drug 
Non-<Jpiate 43(33%) 1.0 
Opiate 133(77%) 4.48 1.9-1.6 
First injected drug Non-opiate 85(49%) 1.0 
O~iatc 99(83%) 3.45 1.6-7.6 
Prison history No 106(55%) 1.0 
Yes 85(82%} 2.30 1.0-5.4 
Methadone history 
No 110(55%) 1.0 
Yes 81(84%) 2.94 1.2-7.3 
Currently on methadone 
No 147(60%) 1.0 
Yes 44(91%} 4.32 0.9-9.5 
Region 
Metropolitan 164(67%) 1.0 
Rum! 27(10%) 0.56 0.2-1.6 
Wgmen (n=llO} 
Sexual orientation 
Heterosexual 88(67%) 1.0 
Bill-lomosexual 35(53%) 0.81 0.2-2.6 
Current primary drug 
Non-opiate 24(44%) 1.0 
Opiate 93(68%) 2.57 0.9-7.5 
First injected drug 
Non-opiate 65(59%) 1.0 
Opiate 55(66%) 0.49 0.2-1.3 
Prison history 
No 107(59%) 1.0 
Yes 17(88%} 3.08 0.6-5.6 
Methadone history 
No 77(49%) 1.0 
Yes 47(85%) 6.80 2.1-2.1 
Currently on methadone 
No 94(56%) 1.0 
Yes 30~83%} 6.35 1.4-9.7 
Region 
Metropolitan 107(63%) 1.0 
Rum! 17(65%) 0.51 0.1-1.9 
Table 6. Percentage of male and female intravenous drug users who were HCV 
seropositive, and odds ratios for seropositivity after adjusting for age and duration 
of injecting (Crofts et al. 1993). 
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Men with a prison history, who used an opiate either as current primary drug or first 
injected drug, and who had a history of methadone or other drug treatment were more 
likely to have contracted HCV. For women a significant association was found with a 
methadone history, and a marginal association with current opiate use. Contrary to the 
findings for the men a negative marginal association was found among females for use of 
an opiate as first drug injected. 
Waddell, 1994, tested 989 injecting drug users presenting to a sexually transmitted 
disease clinic in South Australia. He identified a transmission rate of 29.6% (males, 
26%, females, 36%), with a follow up of 696 individuals. Two people serconverted 
giving an incidence of HCV infection of 3.5 per 100 person-years (95% confidence 
interval (0.4-12.7 per 100 person-years). Tn contrast to the Kaldor study there were a 
higher percentage of amphetamine and occasional injecting drug users than opiate users 
in this study. 
One of the most comprehensive investigations into the transmission of HCV among 
injecting drug users was conducted by van Beek et al. in 1994. Two hundred and one 
known injecting drug users attending the Kirketon Road Centre in Sydney were tested for 
HCV antibodies. Characteristics of injecting drug use and their association with HCV 
transmission are summarised in Table 7. 
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Characteristic Number HCV 95% p-
~revalence (%} Cl value • 
Sex: 
Male 94 55 45-65 
FcmaJc 107 63 53-72 0.3 
Age Group: 
15-19 30 17 3.3-30 
20-24 65 51 39-63 
25-29 44 70 57-84 
30-34 33 70 54-85 
35+ 29 93 84-100 <0.001 
Years since first injecting: 
<3 50 26 14-38 
3-6 29 38 20-56 
6-10 34 62 45-78 
lOt 36 94 87-100 
Unknown 52 77 66-88 <0.001 
·----
Frequency of injecting: 
Occasional 48 40 26-53 
Regular 130 67 59-75 
Unknown 23 57 36-77 0.004 
----
Drugs injected: 
Stimulants only 37 22 8.4-35 
Opiates only 70 74 52-74 
Both 76 63 52-74 
Unknown 18 61 39-84 <0.001 
Sharing of equipment: 
Never 40 38 22-53 
Ever 147 65 57-72 
Unknown 14 36 39-89 o.ocn 
Se1ual practice: 
Homosexual 20 35 14-56 
Bisexual 41 56 41-71 
Heterosexual 107 70 61-79 
Unknown 33 42 26-59 <0.001 
Involvement in sex industry: 
No 107 62 52-71 
Yes 94 56 46-66 0.54 
HIV positive: 
No 180 60 53-67 
Yes 14 57 31-83 
Unexposed 103 42 32-51 
Exposed 95 78 70-86 
Unknown 3 67 13-100 <0.001 
Table 7. Univariate analyses of HCV prevalence among 201 IDUs attending 
Kirketon Road Centre (van Beeket al. 1994) • 
. p value" the signitiCI!!lCC ofthcditTcn:nce in IICV p-cvalcncc between the levels of the [U~;tor indicatOO. 
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Age was significantly associated with JICV prevalence (p<O.OOI) a.~t was length of 
injecting drug usc, frequency of drug usc, opiate usc, sharing of injecting drug equipment 
and heterosexual practices. Those working in the r.cx industry had a slightly lower IICV 
prevalence than those not, 56% vs 62%, though this difference failed to reach statistical 
significance. Exposure to hepatitis B wa~t strongly associated with I ICY (78% exposed 
vs. 42% unexposed (p < 0_00 I)). 
Characteristic OJds Ratio 95•1. Confidence 
Interval 
--·------.--··--~-·---·--- -- --
Years since first injecting 
<] t () 
3~ 1.1 
7-10 2.6 
10+ 19.3 
Unknmm 7.5 
Drug injetted 
Stimulants only 
llcroin only 
!loth 
Unknown 
1.0 
5.9 
5.5 
3.4 
OJ4-3.H 
O.K3-X.4 
2.9-130 
2.1-27 
UH9 
1.7-17 
0.64-JK 
----·- ---· '' -------~ ------ --~---------------------~-
Seiual practice 
Homosexual 
Bisexual 
llctcroscxual 
Unkno\\-n 
---····-··· ------'"'~-A~· 
15-19 
20-24 
25-29 
30-34 
35t -----~~---~~-­Frequency of injecting 
Occasional 
Regular 
p-value' 
0 00 I 
0.011 
0.026 
0.064 
Unknown 0.458 
----------- ------ -~'-"'---~"""-------""""'--
Table 8, Multivariate logistic analysn of IICV prevalence among IDUs attending 
Kirketon Road Centre (van Beek et al. 1994). 
·r vuluc "' the sigiU!kancc of lht..· dilli:rcnu: in I tl'V rn:vak-ncc bt.1wccn the levels of the fattor indicated, y,ha\ all 
other 18ctors in the tBh\c arc mc\udc.-.1 m the logistic model. 
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Multivariate analysis using logistic regression (Table 8), shmvcd significant factors 
involved in IICV transmission to include years since first injecting, drug injected sexual 
practice, age and frequency of injecting. 
Nick Crofts, in 1994, examined the magnitude of the hepatitis C epidemic and its 
implications for future health planning. In this editorial he states; 
"Almost every population of IDU's so far studied has shown very high prevalences of 
exposure to IICV: 90% and more among entrants to methadone programmes. )Q. 70% in 
field recruited and clinic samples in the West. There arc indications of cwn higher rate.'> 
ofHCV infection among IDU's in South·east Asia and South America Risks begin with 
the first injection, and in some populations rates of exposure as high as 40~-0 ha~ occurred 
within 2 years ofhcginning to injL'C\. By the time IDU's have been injt-cting for several 
years, their chances of having been exposed to IICV approach 100% lligh incidences 
have also been observed: 20% p.a. in a cohort in Australia, and 10% p a. in a cohort in 
the Netherlands It is estimated that \here arc as many as 10,000 or more new HCV 
infections per year as a result ofiDU in Australia." 
Crofts eta\., \995, conducted a one year study of all prison entrants in Victoria. A total 
of 3,627 men and women (>99% of all entrants). were tested for hepatitis B and C 
antibodies and HIV antibodies. Of the sample, 1,561 (43%) were injecting drug users 
The prevalence rate among this group was 65.3%, with injecting drug using women 
having the highest scroprcvalence. Table 9 shows the prevalence of IICV antibodies in 
Victorian prisons by gender. 
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Detail Uscnof 
injecting dmg~ 
No use or 
injecting drug! 
Odds ratio 
(95•!. 
confidente 
---------- ___ . __________ ~ _____________________ j~~e_!Yal) ___ ~ 
Men: 
No. by drug use' 
Mean (SD) agc'(years) 
No.(%) anti-I ICY pos 
Women· 
1436 
26.8 (6 8) 
897/1,410 
.. --- _(63(,,L~ 
No. by drug usc' 125 
Mean (SD) agc'(yca<S) 26 8 (61) 
No.(%) anti-JlCV pos 100/118 
~-- _ _ _ ___ (8~8L _ 
All men and women: 1561 
Mean (SD) agc(years) 26.8 (65) 
No.(%) anti-fiCV pos 997/1,528 
(653) 
1749 
31 5(102)"' 
27411,712 9.15 
(16,0) - __ (L7_11J__0_9[:___ 
54 
32.7 (10.6)"' 
14/53 
- (26 4) 
1803 
316(102) 
15.50 
_(6 5to37 c'):__ 
288/1,765 9.61 
(161) _ _ _ (81_to1~4f' 
Table 9. IICV antibody prevalence in pri!lon enlrants in Vicloria, Australia, 
according to use or injccting drugs, October 1991 to September 1992. (Croft, N. eot 
al. 1995). 
• Dr.1g LL..: notlno1u1 li>r Nl n~<:~111fl<-1 Ill """m~~ 1'-' IJ (X!I 
For the duration of the study, 312 entrants were readmitted to prison. These people were 
re-tested. Estimates were calculated for incidence per 100 person years at 38.2 
(Confidence interval: 19.1 to 76.4) for injecting drug users (sec Table 10). 
, _______________ -·-----
Detail No. initially No. ofuro- Mran (SD) Range of Incidence rate 
srro- converten period of observation per I 00 penon 
negative observation days yean (95•/o 
days confidence 
---~---~·---------------
int~ry.!!.) ____ 
Drug 47 8 163 (89) 3-348 38.2 
users (19.1 to76.4) 
Non drug 72 2 171 (89) 4-339 5.9 
users (1.5 to 23.6) 
Total 119 10 168 (89) 3-348 183 
9.8 to 34.0) 
---·--
Table 10. Incidence of inrer.tion with hepatitis C virus among subjeds entering 
prison more than once, October 1991 to September 1992. (Crofts, Net al. 1995). 
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The National Centre for Research into the Prevention of Drug Abuse, Curtin University 
of Technology, has conducted several studies on injecting drug usc in Perth, Western 
Australia between 1994 and 1997. Carruthers and Loxley, 1994, investigated the 
prevalence of HCV among young injecting drug users, age 12 to 20 (n--=234). The 
prevalence rate of HCV among this young cohort was 5.5% (n=6 of 109 tested). 
Characteristics of those positive can be seen in Table 11. 
One significant limitation of this study resulted from the method of blood collection for 
HCV testing_ Fingerwprick collection was noted to be difficult due to clotting of blood 
and in transferring the blood from the thumb to the tube. Revisions of collection 
techniques were instituted, however the initial problems may have resulted in the low 
proportion of samples taken (46%) compared to the questionnaire sample. The 
prevalence rate for this sample may be higher than 5.5%. 
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Gender: 
Male 
Female 
Age: 
15 years 
16 years 
18 years 
19 years 
20 years 
Aboriginal: 
Yes 
No 
Injecting?: 
Yes 
No 
Characteristic 
Drug used mo!Jt often 
Hcroin/llomebakc 
Speed 
Tranquillisers 
Alcohol 
lligh Risk ll<haviour Score(/30) 
I 
4 
6 
8 
10 
Ri!Jky Piercing 
Risky Tattooing 
Duration or injrding: 
less than one year 
three j'eaiS __ _ 
lleard of IICY: 
Yes 
No 
Preferred Drugs: 
Heroin 
Ecstasy 
Amphetamine 
Tranquillisers 
Number 
3 
3 
2 
I 
I 
I 
5 
6 
0 
2 
I 
I 
2 
2 
I 
I 
0 
4 
2 
4 
2 
2 
I 
2 
Table II. Characteri!Jtics or HCV Po!Jitive Re!pondenU (n=6) (Carruthers and 
Lodey, 1994). 
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The 1996 Report of the Australian Study of lllV and Injecting Drug Uso (ASHIDU), 
Bevan, Loxley and Carruthers, provides a comprehensive examination of injecting drug 
use behaviours and prevalence of blood-borne viruses (HBV, HCV and HIV) in a group 
of220 recruits in Perth, Western Australia. 
Characteristic n per % x' p 
groul! 
Age Group 185 72.9 <0.001 
Up to 20 46 15.2 
2lto 25 42 16.7 
26to 30 31 25.8 
3lto 35 30 73.3 
36 years+ 36 88.9 
Treatment 179 36.8 <0.001 
Never 66 12.1 
Ever 113 58.4 
------
Agefl'reatment 179 59.5 <0.001 
Young/never 47 6.4 
Young/ever 36 27.8 
Older/never 19 26.3 
Older/ever 77 72.7 
- -------------
l.ast drug injec-ted 165 13.6 0.001 
Amphetamines 81 27.2 
Opioid 75 56 
_ Q'lter drug ___ 9 33.3 
Duration ofiDU 185 73.9 <0.001 
0-4 years 63 II. I 
5-9 years 51 25.5 
10-14 years 21 61.9 
15 y_cars -t 50 86.0 -~- __ ._ _____ 
Table 12. IICV reactive serology by age, treatment, age/treatment, last drug 
injected and duration or injecting drug use. (Bevan, Loxley and Carruthers, 1996). 
The average age of respondents was 27.5 years, standard deviation 7.5 years, range 14 to 
47 years. Males comprisod 68.6% (n~I51) of the study group. Blood samples for HCV 
testing was collected from 185 respondents, with 7 not supplying blood and 28 supplying 
a sample insufficient for testing. Of the 185 respondents tested, 76 were HCV antibody 
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positive, a prevalence rate of 41.1%, 95% confidence intervals 37.48% to 44.72%. 
Characteristics of those testing positive for HCV antibodies are listed in Table 12. Chi-
squared testing was performed and significant results listed. 
Variables associated with HCV status include: age of the injecting drug user, with the 
higher proportion of those hepatitis C positive in the older age groups; having ever been 
in a treatment group (for example a Methadone programme); combined age-treatment 
groups with young/ever more likely to be reactive to HCV than young/never and 
older/ever more likely to be HCV reactive than older/never; amphetamine users less 
likely to be HCV reactive than opioid users and duration of injecting drug use. Age and 
length of injecting drug use were highly correlated, r = 0.88 (Bevan. Loxley and 
Carruthers, 1996). 
Hando et a1 (1997) profiled the demographic, drug use and criminal correlates of 279 
youths detained in New South Wales Juvenile Justice Centres. A quarter of the sample 
(24%) had injected an illicit drug. Three-quarters (77%) of those who had used heroin 
and two-thirds (64%) of those who had used amphetamines had injected those 
substances. One-third (37%) of those who had injected reported using a needle before or 
after someone else had used it, and 18% reported doing so in the month before detention. 
Over half(58%) of those who had shared needles in the past month did not always clean 
them. 
Crofts and Aitken (1997) assessed the incidence of blood-borne infection among a cohort 
of injecting drug users over the period 1990 to 1995. Annual hepatitis C prevalence rates 
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among this cohort ranged from 81% in 1990 to 69.6% in 1995 (lowest rate, 67.'?/o in 
1993), although it is not clear if all participants were tested each year. Incidence rates 
were also calculated and are given below. 
1990-1991 1992-1993 1994-1995 Overall 
hepatitis C virus 
Seroconverters 5 ~ 6 19 
Person-years at risk 30.1 73.4 74.1 177.6 
Incidence (per 100 py) 16.6 10.9 8.1 10.7 
95%Cl 6.9-40.0 5.5-21.8 3.6-18.0 6.8-16.8 
Table 13. Biennial incidence of hepatitis C virus in a cohort of Victorian injecting 
drug users, 1990-1995. (Crofts and Aitken, 1997). 
Loxley et al (1997) were investigators in the 1994 Australian Study ofiDV and Injecting 
Drug Use (ASHIDU). Their paper reports age standardised infection rates of hepatitis C 
across four Australian cities. In Perth, Western Australia,. the infection rate for males 
was 56.4% and for females 44.1%. 
City Men 95%CI Women 95°/o CI 
Adelaide 54.4 50.0-58.8 51.3 45.5-57.1 
Melbourne 61.1 56.7-65.5 63.3 57.8-68.8 
Perth 56.4 52.0-60.8 44.1 37.5-50.7 
Sydney 73.1 69.2-77.0 68.4 62.8-74.0 
National 59.4 57.2-61.6 58.6 56.6-61.6 
Table 14. Age-standardisetl hepatitis C prevalences and confidence intervals, by city 
and gender (Loxley et al, 1997). 
The Fitpack Study, (Lenton & Tan-Quigley, 1997), examines the injecting drug patterns 
and behaviours of recreational and occasional injecting drug users. This cohort 
traditionally have minimal contact with conventional drug treatments agencies and 
represent an unknown subgroup for this population. Accessed by questionnaire through 
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the sale ofFitpack:s (needle and syring'~ packs), 513 responded, a response rate of200/o. 
Hepatitis C questions were self-report only, where 64.9% reported testing for HCV, with 
those positive for the virus 25.2%. While this rate is lower than the ASIDDU sample 
(Bevan, Loxley and Carruthers, 1996}, mean length of lifetime injecting is 
correspondingly lower. Table 14 illustrates key variables associated with self-reported 
HCV te..'"ling. 
Positive BCV result (o/o) 
No Yes o(l) sig(2) 
Under 26 y.,..-s of age 60.5 14.9 292 0.0000 
Females 46.6 38.1 275 0.2769 
Are married or living with sex partner 47.0 52.0 295 0.5417 
Have children 41.4 58.8 290 0.0143 
Are employed 47.0 29.8 296 0.0135 
Live in the city 87.8 84.6 245 0.6983 
Firstinjectedatlessthan 18yearsofage 46.1 41.7 286 0.6128 
LessthanlOyearsofinjecting 79.1 21.9 281 0.0000 
Stimulants injected with this Fitpack 67.9 36.3 296 0.0000 
Depressants injected with this Fitpack 43.0 82.2 296 0.0000 
Injected stimulants in past month 76.8 46.1 296 0.0000 
Injected depressants in past month 51.3 81.7 296 0.0000 
Injected at least daily in past month 34.9 61.3 296 0.0001 
Shared needles in past month 40.9 44.2 296 0.7246 
Shared other equipment in past month 55.7 59.3 296 0.6864 
Prior contact with specialist drug agency 55.4 29.6 289 0.0001 
Have been charged with a drug offence 50.1 75.2 296 0.0003 
Table IS. Self reported positive Hepatitis C result by key variables for those 
l.lepntitis C tested: Percent -respondents. 
1) Each row represents 2 cells of a 2x2 contingency table and n is overall value for a/14 cells of the 
2x2 table. 
2) Chi-squared le~·t corrected for continuity. Bonfe"onl adjustment was employed at on experiment 
wise error rate of0.05 which set alpha for each comparison at a 0029. 
Those teming positive for HCV were more likely to have children, to have been charged 
with a drug offence and to have had contact with a specialist drug treatment agency. A 
positive HCV result was associated with having injected for 10 or more years, injecting 
depressants with the Fitpack and having had contact with a specialist drug treatment 
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agency. Length of duration of injecting drugs in predicting HCV positivity remained 
consistent with earlier research (Bevan., !..oxley & Carruthers, 1996; van Beck et al. 
1994). The Lenton study reports those respondents injecting for under 10 years had a 
self-report HCV positivity rate of 6. gofo while for those injecting for 10 years or more, the 
rate was 52.5% (Lenton, S & Tan-Quigley, A. 1997). 
4 years or less 
5-9 years 
10-14 years 
15+ years 
Fitpack (n=285) 
2.1% 
13.4% 
52.7% 
52.4% 
Ashidu (n-140) 
7.golo 
30.8% 
55.6% 
75.6% 
Table 16. Percentage of respondents positive for hepatitis C by length of use. 
(Lenton, S & Tan-Quigley, A. 1997). 
Lynskey and Hall (1998) examined changes in age of initiation to heroin use over time. 
They examined results of both the AN AlDUS and ASHIDU studies comparing age of 
initiation to heroin use with the respondent's decade of birth (see Table 16). While the 
mean change in age of initiation was not statistically significant there was a consistent 
decrease among heroin us:~rs born in later decades. 
Mean age at first heroin use 
AN AlDUS ASHIDU 
Decade of Males Femsles Persons Males Females Penons 
birth 
1940-1949 20.1 20.5 20.2 26.1 26.0 26.1 
1950-1959 18.4 17.6 18.2 20.2 20.8 20.3 
1960-1969 16.7 17.5 17.0 19.4 20.5 19.8 
1970-1979 14.8 14.7 14.7 17.5 17.5 17.5 
Table 17. Mean age at first heroin use for respondenh born in different decades. 
(Lynskey and Hall, 1998). 
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The National Centre in lllV Epidemiology and Clinical Research produces an Annual 
Surveillance Report on HIV/AIDS, Hepatitis C and Sexually Transmissible Infections in 
Australia. Nationally, more than 125,000 persons have been diagnosed with hepatitis C 
infections since 1990. Sin~ 1994 the number of new cases has remained relatively 
stable at 18,000 to 20,000 per year. It is estimated that the number of known cases 
represents 600/o of all cases of hepatitis C in Australia, based on duration and severity of 
disease and known efficacy of reporting systems (Annual Surveillance Report, 1999). 
Injecting drug use is the major transmission factor in 75% to 80% of all Australian cases. 
In Western Australia the number of newly diagnosed case of hepatitis Care as follows: 
v ... 
1994 
1995 
1996 
1997 
1998 
Number of persons 
1,314 
1,146 
1,146 
1,137 
1,261 
Rate per 100,000 
population (June 1996) 
74.4 
64.9 
64.9 
64.4 
71.4 
Table 18. Number and rate of diagnosis of hepatitis C infections 1994--1998 for 
Western Australia. (Annual Surveillance Report, 1999). 
Nationally, diagnosis ofhepatltis C by age group and gender for1998 are as follows: 
Age group (years) Male Female Total• 
0-4 69 60 133 
5-14 25 21 46 
15-19 724 659 1,401 
20-29 3,416 2,239 5,738 
30-39 3,823 2,270 6,136 
40-49 2,521 1,129 3,673 
5().59 393 221 619 
60+ 368 309 687 
Not known 24 8 41 
Total 11,363 6,916 18,474 
Table 19. Number of diagnoses of hepatitis C infection, 1998, by age group and sex 
(Annual Surveillance Report, 1999). 
*Totals include diagnoses in people whose sex was not reported 
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Crofts et al (1999) compared transmission rates of hepatitis C and HlV among Australian 
intravenous drug users. They identified a prevalence rate of hepatitis C of 65% and 
estimated the incidence of new cases to be in the order of 6, 000 to 10,000 per year across 
Australia for this group. 
2.3 Incidence and Prognosisof Ci"hosis and hepatocellular Clli'Cinonuz. 
Crofts ( 1994) stated that the majority of persons exposed to hepatitis C become 
chronically infected. 
""Among an unknown proportion, there is an incubation period of20-30 years to end-
stage liver disease and in a smaller proportion to hepatocellular carcinoma." 
In 1997, Alex Wodak summarised the incidence and prognosis of hepatitis C infected 
persons as follows: 
"About 200/o develop cirrhosis over a 20 year period of whom about 5% develop liver 
failure and another 5% liver cancer within 5 or more years. Complications of chronic 
hepatitis C infection will result in many patients requiring frequent hospitalization. 
Perhaps 500/o of people with chronic hepatitis C develop a lingering illness with 
debilitating fatigue precluding employment and often home duties. Fatigue may be one 
of the most expensive aspects of the hepatitis C epidemic." 
Yano et al (1994) quantified the survival rate of persons with hepatitis C induced 
cirrhosis. Ten years after being diagnosed with cirrhosis of the liver 62.3% were still 
alive, however, after fifteen years this number had decreased to 35.9"/o. 
2.4 Injecting drug use practices. 
There are many practices undertaken by injecting drug users that put them at risk of 
contracting blood-borne viruses. These include; the sharing of needles and other 
injecting equipment, unsafe sexual practices and high risk tattooing and body piercing. 
Other environmental factors that appear associated with an increased risk of contracting 
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hepatitis C include type of drug injected, participation in methadone programmes, 
incarceration and co-infection with hepatitis B and or the human immunodeficiency virus 
(HIV). 
Ross et al (1993) compared needle sharing practices among respondents of the two 
ANAIDUS studies undertaken in 1989 and 1990. As different groups of respondents 
were sampled for each study, results here are a comparison of practices across time rather 
than across individuals. 
Description 
Number of times needles & syringes used before too 
worn to use again 
% of times use new needles and syringes 
%of times easy to get new needles and syringes 
Number of times new needles & syringes obtained when 
using 
%of time needles & syringes used after someone else 
%of time needles & syringes used first then shared 
Number of people accepted used needles & syringes from 
in past 6 months 
Number of people who used a needles & syringe before 
it's discarded 
Reasons for sharing 
Factor 1: Don't care when withdrawing or intoxicated 
Factor 2: Unavailability of equipment 
Factor 3: Belief that risk is low 
Time since last used needles & syringes after someone else 
Never 
Years 
Months 
Weeks 
1989 
2.9±3.1 
73.5±26.2 
84.3±20.7 
65.6±102.3 
19.0±25.8 
50.9±32.4 
1.8±6.6 
2.0±4.2 
5.1±1.7 
0.3±0.6 
0.5±0.7 
19.4 
27.8 
30.2 
13.9 
1990 
1.9±2.3 
84.8±21.8 
93.0±14.3 
37.4±62.2 
9.7±18.5 
38.2±35.8 
0.9±3.9 
1.2±1.1 
6.0±1.6 
0.1±0.4 
0.2±0.5 
31.0 
28.2 
27.3 
8.2 
8.6 5.3 Dey•----------------------------------~~----~~-­
T&ble 20. Comparison of needle sharing practices in the 1989 and 1990 ANAIDUS 
studies (Ross, Stowe, Wodak and Gold 1993). 
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There was a downward shift in the rate of needle sharing in the year between sampling 
with a corresponding increase in the use of new needles and syringes. Of concern is the 
13.5% of respondents in 1990 who conceded sharing daily or weekly. 
Studies conducted by the National Centre for Research into the Prevention of Drug 
Abuse, investigating the rate of needle sharing among injecting drug users, all utilise a 
common measuring instrument, the High Risk Behaviour Scale (HRBS). This six item 
questionnaire examines frequency of drug use in the last month, frequency of using a 
needle after someone else in the last month, number of people that used the needle 
previous to the respondent in the last month, frequency or cleaning needles that other 
people have used prior to re-use in the last month, frequency or the usc or bleach after 
someone has used the needle prior to re-use in the last month and the frequency or 
someone using a needle after the respondent in the last month. Respondents are given 
the choice of six responses rated from 0 to 5, giving a possible totaJ of30. 
Levelofrisk 
No risk (score- 0) 
Low risk (score"' 1- 2) 
Moderate to high risk (score> 3) 
No risk no sharing in the past month 
%or injectors 
20.4 
38.9 
40.8 
Low risk= shared once with one or no person in the last month 
Number 
32 
61 
64 
Moderate to high risk= shared more than once with more than one person in the past month. 
Table 21. HRBS scores for injectors (ever injected) (n = 167) (Carruthen and 
Loxley, 1994). 
One hundred and sixty seven respondents involved with The Hepatitis C and Young 
Drug Users Study (Carruthers & Loxley, 1994) completed the HRBS. Scores ranged 
from 0 to 24 with a mean score of3.5 (sd = 5.36, 95% confidence interval 0- 14.6). The 
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results were further subdivided into three groups, no risk (HRBS = 0), low risk (HRBS = 
I -2) and moderate to high risk (HRBS > 3). 
Mean HRBS were significantly lower for amphetamine users when compared to heroin 
and homebakc users (F1 = 5.93; p = 0.01). Seventy three percent (n·=J28) of those who 
had ever injected illicit drugs reponed sharing other injecting equipment in the preceding 
twelve months. These included spoons, filters, cups and glasses, the drug moe, 
tourniquets and swabs (Carruthers & Loxley, I 994). 
Van Beck et al, (1994), reported on a number of behavioural characteristics of 201 
injecting drug users in Sydney, New South Wales. Among occasional injectors, 40% 
were hepatitis C positive, while 67% of regular injectors were infected with the virus. 
When frequency of sharing injecting equipment was investigated, 38% of those who had 
never shared equipment were infected, as were 65% of those who had shared. 
Two hundred and twenty respondent:; completed the IIRBS in the ASHIDU study 
(Bevan, Loxley and Carruthers, 1996). The mean score was 3.1 (sd 3.8; range 0 to 20). 
Table 22 shows the frequency of responses for each question. 
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~~~~--------------------~~-SuiJ.scale _ite_l!!_________ _ __ _,_,II"R"B"S,_!I_(ore __ _!_!!9.uenc.r__~---
Number of times injedcd in the put mO;;I-11 220 
Hasn't injcr.tcd 0 26 11.8 
Once a week or less I 70 31.8 
Morcthanonccawcck 2 91 41.4 
Onccaday 3 17 7.7 
2-3timcsaday 4 13 5.9 
More than three timl.'S ada · 5 3 1.4 
Number of times used a needle after 
someone else in past month 
No times 
One time 
Two times 
3-5 times 
6-10 times 
More than I 0 times 
0 
I 
2 
3 
4 
5 
_ M~~in_g ~~- ---------------- ____________________ _ 
Number of different people used needle before you in past month 
None 0 
One person I 
Twopcoplc 2 
3-5 people 3 
6-10 people 4 
More than 10 people 5 
Missing data 
How often in the last month cleaned needles before reusing them 
Docsn • t re-use 0 
Every time I 
Often 2 
Sometimes 3 
Ran:ly 4 
Never 5 
How often in last month cleaned need~ with bleach before re-
using 
Doesn't re-use 0 
Every time I 
Often 2 
Sometimes 3 
Ran:ly 4 
Never 5 
How many times in the last month has someone 
used a needle after you have used it. 
Notimcs 0 
Onetime I 
Tv.'O times 2 
3-5 times 3 
6-IOti:ncs 4 
More than I 0 times 5 
Missing data 
220 
185 H4.1 
14 6.4 
5 2.3 
9 4.1 
2 0.9 
3 14 
2 0.9 
·-~-·----- -------
220 
185 H4.1 
31 14. I 
3 14 
() 0.0 
0 0.0 
0 0.0 
I 0.5 
220 
IH5 H4.1 
27 12.3 
2 0.9 
I 0.5 
2 0.9 
3 1.4 
220 
185 H4.1 
15 6.8 
I 0.5 
I 0.5 
0 0.0 
18 H.2 
220 
186 H4.5 
12 5.4 
9 4.1 
9 4.1 
I 0.5 
0 0.0 
3 14 
Table 22. Frequency and percentage of responses to questions comprising the 
IIRBS Jrug Uses sub Scale (Bevan, Lol.ley and Carruthers, 1996). 
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When questioned about sharing of needles at the last injecting occasion, 90.7% reponed 
using a new needle with 7.2% reponing sharing of needles {Table 23). 
··~urncy Prrcc-ntage •;. 
---····--·-. -·- -· -------·-----·---·-------· 
Used new needles only 
Used anothers nredles 
Regular sexual panncr 
Close friend 
Reused own needlrs 
176 90.7 
5 
3 
2.6 
1.5 
Injected alone 4 2.1 
Injected with one oth1:r 4 2.1 
_l~ject~~ ydth mo!~.~~~--'!.I!~ .. !Jih~-- ____ ·--··-··- ____ 2 _____ ·-- --···- ____ _J_:_O __________ _ 
Table 23. Self-reported u-use and sharing of n«dles on the last injecting occasion 
for respondents who had inj«ttd in the last month (n=194) (Bevan, Los.ley and 
Carruthers, 1996). 
The Youth, AIDS and Drugs Study (Loxley, 1997), reports a mean HRBS score of 4.1, 
range 0-29, sd 5.6. The respondents for this study were aged between 14 and 20 years of 
age and arc therefore comparable to the 1994 Hepatitis C and Young D111g Users study 
{Carruthers and Loxley, 1994). Respondents were assessed for risk management 
strategies related to their injecting drug use. The results are summarised in Table 24. 
Accept used needles from no-one 
Accept used needles from lover or friend only if bleached 
Accept used needles only from lover 
Accept used needles only from a lover or close friend 
Frequency 
35 
12 
22 
8 
PercenUge 
Unclear 2 
----------------=-----
44 
15 
28 
10 
3 
Table 24. Risk management strategies for injecting: Injectors (n = 79) (Carruthers 
and Loxley, 1994). 
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The Fitpack study (Lenton & Tan-Quiglcy, 1997) analyses the HRBS scores calculated 
from this study against ASHIDU data using the Chi~squared test (Table 25). Subjects of 
the Fitpack study reported injecting, receiving a used needle and passing on a used 
needle more frequently than those in the ASHIDU study (Bevan, Loxley & Carruthers, 
1996) and were more likely to have used a needle after a larger number of people. 
Respondents were also asked the frequency of sharing other injecting equipment in the 
last month. Of the 510 responses only 41.5% reported never sharing equipment and 
nearly 245 sharing on ten or more occasions (Table 26). Logistic regression analysis 
demonstrates that those likely to share equipment arc more than four times as likely to 
have an income less than $10, 000 and four times as likely to have shared needles in the 
past month. 
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"I• RESPONDENTS 
Sub-scale item l<'itpack ASHIDU(11 
Number oftimes injected in the p111t month 
Hasn't injected 3 .I 
Once a week or lcss131 21.1 
More than once a week but not daily 37 .I 
Once a day 14.8 
2-3timcsaday 16.7 
More than three times a day 7.3 
Number oftimes used a needle after someone else in past month 
No times 72.3 
O•ti= I~ 
Twotimes 7.0 
3-5 times 5.4 
6-!0timcs 1.3 
More than I 0 times 3. I 
Number of different people used needle befiJre you in past month 
11.8 
31.8 
41.4 
7.7 
5.9 
1.4 
84.8 
6.4 
2.3 
4.1 
0.9 
1.4 
Sig.(pt1 
0.0000. 
0.0000 
None 72.9 84.5 0.0000 
Oncpcrson 15.6 14.2 
Twopcople 5.0 1.4 
3-5 people 3.7 0.0 
6-10 people 1.9 0.0 
More than 10 people l.O 0.0 
How often in last month cleaned needles with bleach before re-using 
Docsn 't rc-usc1~1 72.2 84.1 0.0000 
Every time 6.8 6.8 
Often 1.7 0.5 
Sometimes 5.3 0.5 
Rarely 8.1 0, 0 
Ncvcr41 5.7 8.2 
Table 25. Comparison ofiiRBS scores Fitpack vs Perth ASHIDU. (Lenton & Tan-
Quigley, 1997). 
I) ASHIDU dat. is in Valid percent (excludes missing data) 
2) Test is non (t.tr.Unctric Chi squared Where expected frequency less than 5 cells were collapsed. 
3) Collapses two response categories in Fitpack 
4) Estimated fa1ucs as described above. 
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Number or times Frequency percentage D/o 
Never 212 41.5 
Once 30 5.8 
Two times 33 6.6 
3~5 times 79 I 5.5 
6-10 times 34 6.8 
More than I 0 times 122 23.9 
Total 510 100.0 
Table 26. Times in past month respondent shared other injecting equipment 
(Lenton & Tan-Quigley, 1997). 
Dolan et ai (1998) described a mathematical model of IDV transmission in New South 
Wales prisons. Parameter estimations of the mean number of shared injections per 
injecting drug user inmate per week ranged between 0.13 and 0.41. 
Crofts et al ( 1999) reported an incidence of hepatitis C of 4% to 11. g<'/o per year among 
intravenous drug users who reported never sharing needles and 17% to 30.2% per year 
among those who did. 
The 1999 Annual Surveillance report, in a survey of persons using needle and exchange 
programs reported rates of needle sharing at between 9% and 21% in 1997 and 1 00/o and 
29% in 1998. 
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Year 
1997 
1998 
Injecting less than three years 
Injecting more than three years 
Not reported 
Injecting less than three years 
Injecting more than three years 
Not reported 
Male(%) 
II 
13 
II 
13 
17 
19 
21 
15 
22 
24 
20 
14 
Total(%) 
15 
14 
14 
17 
18 
18 
Table 27. Rate of needle sharing by duration of use and year of IDUs accessing 
needle and exchange programs. (1999 Annual Surveillance Report). 
2.5 ~'ti!mmission through needle sharing. 
In 1993, Waddell reponed prevalence rates of hepatitis C among clients attending a STD 
clinic in South Australia. Follow up testing was undertaken among 73 clients and an 
incidence rate of3.5 per 100 person years (95% C.l. 0.4 to 12.7) was determined. 
Crofts, Stewart, Hearne et a1 (1995) assessed the spread of bloodborne viruses among 
entrants to Victorian prisons over a twelve month period from 1991 until 1992. They 
calculated a hepatitis C seroconversion rate of 18.3 per 100 person years (95% C. I. 9.8 to 
34.0) for the total sample (3429 males and 198 females). Among only those entrants 
identified as intravenous drug users the seroconversion rate was 38.2 per 100 person 
years \95% C.l. 19.1 to 76.4) and among those aged 30 years or less the incidence was 
41.0 per 100 person years (95% C.l. 20.5 to 82.0). 
Crofts and Aitken ( 1997) examined the incidence of hepatitis C and risk behavio1~rs 
among a cohort of Victorian injecting drug users. Respondents were interviewed at least 
three times over a five year period (1990 to 1995) and were grouped according to reports 
of needle sharing or not at each interview. Results indicate that although 66 respondents 
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reported never sharing needles or syringes, 65% were hepatitis C positive, with two 
seroconverting over the study period. This led to speculation that the virus was being 
transmitted via other injecting equipment, for example, the sharing of water and swabs. 
Reports of sharing of BCV Sero- Person- Incidence per 
Needles and syringes status converters years at 100 py (95%CI) 
+ risk 
Half or more of all 
interviews (n=63) 14 49 6 35.5 16.9 (9.8-48.5) 
Fewer than half of all 
interviews (n:=73) 21 52 7 48.6 14.4 (6.0-24.0) 
None(n~66) 23 43 2 46.4 4.3 (1.5-14.3) 
Table 28. Hepatitis C virus prevalence and incidence among 202 injecting drug 
users interviewed three times or more, by levels of risk, 1990-1995 (Crofts and 
Aitken 1997). 
In 1997 Crofts and colleagues investigated the epidemiology of hepatitis C infection 
among Australian injecting drug users. 
By examining the prevalence and incidence rates of two independent studies they 
calculated hazard rates and mean times until infection for injecting drug users in New 
South Wales and Victoria. Little difference was observed in the mean time to infection 
between the two groups (approximately 7 years). 
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Injecting drug use Total Mean time to 
Started before Started since infection (y) 
1987 1986 (95%CI) 
Victoria 
Hazard mtc (95o/..Cl) 0.171 0.129 0.146 6.9 
(0.126, 0.169) (5.9, 7.9) 
Rate ratio (95%Cl) 1.32 
(0.82, 2.14 
Sydney 
Hazard mtc (95o/..CI) 0.258 0.129 0.148 6.8 
(0.115, 0.188) (6.0, 8.7) 
Rate mtio (95o/..CI) 
Combined 
Hazard rate (95o/..CI) 0.129 0.147 6.8 
(0.133, 0.229) (0.129, 0.166) (6.0, 7.8) 
Rate ratio (95o/..CI) 
Table 29. Seroconversion bazard rates and means times to infection with HCV 
among injecting drug users in two independent studies in Victoria and Sydney 
(Crofts et al1997). 
Crofts, Aitken and Kaldor (1999) attempted to explain the vastly differing rates of 
transmission of HIV and hepatitis C among intravenous drug users by modelling the 
probability of infection as a function of an infectivity rate. While the authors 
acknowledged the estimates were crude results were as fullows: 
IVDU population prevalence rate (A) 62.4% 
Carrier rates (B) 80'/o 
Needlestick infection probability estimates (C) 
High 10.0% 
Low 2.7% 
Probability of infection (AxBxC) High 4.9% 
Low 1.3% 
The authors estimated a probability of infection with hepatitis C of between 1% and 5% 
for each needle sharing act. 
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THE MATHEMATICAL MODEL 
3.1 Background to Mathematical Models. 
Mathematical models related to infectious diseases in humans in the early 1990's 
concentrated in the main on modelling the transmission and spread of1-0V/AIDS within 
one and two sex communities (Anderson and May, 1989; Castilla-Chavez, 1989; 
Comiskey, 1993; Comiskey et a1. 1993). During this time, research on hepatitis C had 
focussed primarily on transmission rates and modes as described in Chapter 2. As more 
data became available researchers have begun to construct mathematical models to 
predict the long-term spread and effects of the disease. 
Mather and Crofts (1999), constructed a computer simulation of a Markov model to 
account fur the large number of parameters and hig~1levcls of variation associated with 
hepati' :s C transmission among injecting c:i.~g <Jsers. Their examination of previous 
infectious disease models, such as influenza and measles, suggested a shon disease 
interval where the individual was only infectious for the span of the disease, leading to 
complete recovery. At this stage the individual had either developed a long-lasting 
immunity or returned to a susceptible state, as in the case of influenza. Few models had 
examined disease processes, such as hepatitis C, where infection and illness are a long-
tenn proposition, with d'Xades long incubation periods and enduring infectious states 
after recovering from acute infection. 
Mather and Crofts used a stochastic micro-population model that essential followed the 
history of distinct individuals. This was done by dividing their cohort into sub-
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populations in order to define the parameters at a group level and allow controlled 
experimentation within each group. An example of such a group is a prison population, 
where the prevalence rate is distinct and who have different behavioural characteristics to 
other groups. The system was treated as a finite-state stochastic process, however as the 
time units were small in comparison to the natural history of the infection, the process 
was treated as a Markov simulation. The stages of the disease process were described as 
those who were susceptible to infection, those infected and those who removed 
themselves from the population (removals) or died. Their results demonstrate a high 
sensitivity to very smaJI changes in the interaction levels within the groups and to 
changes to the probability of infection through a single contact with an infected person. 
The use of a closed population was seen as a limitation to this model and the authors 
speculated that an open population would allow them to assess how a reduction in the 
level of interaction would affect the prevalence rates. 
Law (1999) developed models of the hepatitis C epidemic in Australia based on 
estimates of the pattern of injecting drug use. Due to the paucity of accurate data on the 
numbers of injecting drug users in Australia, the Delphi technique was used to achieve 
consensus estimates for the number of regular and occasional lOU's. Seventeen experts 
participated by completing a brief questionnaire used to estimate regular and occasional 
injecting drug use, with a second iteration performed by all participants. It was estimated 
that there were 100,000 regular and 175,000 occasional injecting drug users in Australia 
in 1997. Assumptions such as the HCV incidence rate among both groups, infection 
rates from transfusion or other transmission routes, the natural history of the disease and 
progression to cirrhosis and hepatocellular carcoinoma (HCC) were made from existing 
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studies or Government reports. Because of the uncertainty of some of these assumptions, 
extensive sensitivity analyses were performed on these parameters using upper and lower 
limits. 
The models developed by Law indicated there were 196,000 (range 149,000- 234,000) 
individuals with hepatitis C in Australia in 1997, increasing at a rate of 11,000 (range 
8,500 -13,500) new infections. The models also indicate 47,000 (35,000- 60,000) had 
cleared the disease, 134,000 (1 01,000- 167,000} had chronic HCV infection, 8,500 
(4,000 -13,000} has HCV-related cirrhosis and SO (40- 130} had develop HCC in 1997. 
Kane et. al. (1999) produced a simple mass-action model utilising a general linear 
equation with variables representing the prevalence of a pathogen in a population, the 
transmission efficiency of the pathogen, the susceptibility of a population to that 
pathogen. the transmission efficiency of the pathogen, the proportion of unsafe injections 
and the number of injections a person receives. This research, prepared for the World 
Health Organisation, specifically addressed unsafe injecting practices among developing 
countries, where immunisation programs and medications are delivered via reused, 
unsterilised needles. The equation used to estimate an individuals risk of becoming 
infected is: 
P(1) = 1-(l-P(s).l'(t)P(e))" 
where P(l) is the probability of an individual becoming infected each year, P(s) is the 
probability that an individual is susceptible to the pathogen, P(J) is the probability that 
the organism will be transmitted via injecting equipment contaminated with infected 
blood, P(e) is the probability the individual is exposed to contaminated injecting 
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equipment and n is the number of injections an individual receives in one year. P(e) is a 
function of the prevalence of a virus, P(v) and the proportion of injections that are 
unsafe, P(u), whereP(e) P(v).P(u). Susceptibility was a function ofHCV in the 
particular population, where P(s) I- Prevalence(HCV-posltive individuals). The 
simple massMaction linear model estimated 2.3 -4.7 HCV infections per year resulting 
from unsafe injecting practices in the developing world. The authors go on to qualify 
their results, indicating there is no practical way to estimate the number of injections 
given outside the health sector in these countries, and that more complex. stratified 
models may produce more accurate estimates. 
In a dissertation prepared by Zhanhai Gao (200 1 ), mathematical models were prepared to 
model the human immunodeficiency viruse (lllV) and hepatitis C virus (HCV) 
epidemics in Australia. Gao derives a dynamical model of the HIV and HCV epidemics 
through needle sharing among injecting drug users and simulations ofthe prevalence 
and incidence of these viruses among IDU' s are made. The effects of needle sharing and 
cleaning of equipment is examined. The second part of his model assesses the 
epidemiological consequences of injecting drug use and sexual transmission ofmV in 
Australia and examines the effect of highly active antiretroviral therapies on the IDV 
epidemic. 
In 2003, Freeman and associates conducted an ecologic analysis to predict the 
progression of cirrhosis in chronic hepatitis C virus infection. The ecologic analysis was 
u'Jed to estimate the relative risk of cirrhosis for factors identified as significant in 
fibrosis progression. Factors included ethnicity, sex distribution, alcohol consumption, 
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age at infection, mode of HCV infection, serum transanimase levels, histological 
evidence of infection. HBV status, HIV co-infection and viral load. A time period of20 
years ofHCV infection was used. In order for the relative risk of cirrhosis to be 
estimated using linear regression techniques, a transformation was performed: 
y = In { -Jn[l- cirrhosis(20)]} and then least squares linear regression lines were fitted 
for y = !lm.~<»ltgury + xp ft>c!'.ll'. Confidence intervals were based on the standard error of 
the slope of the regression line. The relative risk of cirrhosis, RRJ.xtor = cxp(p f.xto•) , was 
estimated and a stepwise multiple linear regression was performed to adjust for 
colinearity between factors . 
. Feeeman et. aJ. found that male sex (RR = 1.08), heavy alcohol consumption(RR = 1.61), 
elevated serum ALT (RR = 1.23) and histology demonstrating high-grade 
necroinflammatory activity were all factors independently associated with progression to 
cirrhosis. Other factors were not found to be significantly influential. 
Law et. al. (2003), rt:~ined earlier published models, (Law, 1999), to provide a overview 
ofHCV incidence, prevnlence and long-term prognosis in 200 I. Using methods 
described previously (Law, 1999), and recent published data from research and 
government reports, a more accurate picture of the incidence and prevalence ofHCV 
infection in Australia was developed. Their results indicated that in 2001, the number of 
people with HCV antibodies numbered 210,000 (157,000- 252,000) with and incidence 
rate of16,000 (11,000- 19,000) that year. Of these 83% of cases were estimated to be 
due to injecting drug use, 5% due to blood transfusions and 9% due to other transmission 
routes. They further estimated that by 2020, there would be 836,000 Australians living 
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with HCV infection. The number of individuals with cirrhosis, in 2001. was estimated to 
be 6,500 (5,000- 8,000) and 50 (40- 60) cases ofHCC. 
Murray et. al. (2003) constructed a mathematical model using differential equations to 
assess the impact ofbehavioural changes on the spread ofHIV and HCV among injecting 
drug users. The model described J(t) the number of lOU's who are infectious at timet. 
Parameters for this model are; al. the average rate of new infections per year, hi, the 
average rate of loss each year of infected lOU's through all means and c, the rate of new 
infections per year from non-needle-sharing means. This gives: 
d! 
-=al-bl+c 
dt 
The parameter, a, i:,; calculated, a = p(l- d)mu(n,a), where pis the probability of 
infection through sharing a needle or equipment, 11 is the average number of lOU's using 
the same equipment per episode, m is the average number of injecting episodes per year, 
dis the fraction of needles that are cleaned before use, and 11 is the number ofuninfected 
lOU's at risk. 
For each individual, the number of people they have shared needles with over one year is 
defined by m(n-1). The critical sharing level for incidence sci = m.,(n., -1)/2, is 
determined when 
b:::: a" 
= p(l- d)m.(n. -1)/2 
Hence 
Zb 
s. = m (n. -I)=---;::-::-
• p(l-d) 
Page 59 
Critical sharing levels for prevalence, 5cp, are calculated; 
scp = mcp(n"P -I) ::. 2(h + r) , where r is the annual rate of increase in total IOU numbers. 
p(l- d) 
The authors discussed their results in light of the impact that needle exchange programs 
and the resulting lowering of needle sharing. The impact on the incidence ofHIV after 
the late 1980's is quite marked however the impact on HCV incidence is less so. This is 
thought to be due to higher infectivity ofHCV through needle sharing than HIV. 
3.2 MaJheltllllica/ Model.< 
It is proposed to initially construct a single sex model of the SIR form described by 
Anderson and May, 1989, utilising three separate stages, those Susceptible (S), those 
Infectious (1) and those in the Removal (R) category. The usc of non-linear differential 
equation transmission models will be employed. 
The population will be divided into three categories; those susceptible to infection 
(susceptibles), those currently infected (infectious) and those that progress to a chronic, 
non-infectious state or death (removals). Unlike models constructed to simulate 
H1V/AIDS transmission, where removals arc designated by conversion to AIDS, 
hepatitis C docs not have a clear transition stage. Development of cirrhosis or 
hepatocellular carcinoma will be used as the point of transition to the removals category. 
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The model will be age dependent with subgroups that denote duration of injecting. This 
subgroup structt:J ":arises from studies outlined in Chapter 2, where one of the key factors 
ofHCV transmission related to duration of drug use. In Table 5 (Croll ct. al., 1993), we 
sec how prevalence rates arc dependent on the number of years the individual has been 
injecting drugs. For this reason these subgroup will be divided in the same manner and 
will be denoted as l, those with 0-4 years injecting; 2, those with 5-9 years injecting; 3, 
those with 10-14 years injecting and 4, those with 15 or more years injecting. 
As explained by Anderson and May, 1989, the number ofsusccptib1e IVDU's increase 
due to recruitment and decrease following transition to the infectious class afier m .. 'Cdle 
sharing. A decrease in the infectious class occurs as a result of normal migration rates 
out of injecting populations. The rate of change in the number of infectious depends on 
recruitment from susceptibles and where transition to active hepatitis C and 
cirrhosis/hepatocellular carcinoma among infectious occurs. A natural attrition for both 
susceptibles and infectious will also occur due to death by drug and other disease-related 
causes. Finally the rate of change in the removals class is determined by those that arc 
infectious and develop cirrhosis/hepatocellular carcinoma, and loss due to death and 
normal migration out of the drug using population. 
Once developed the model will be solved by numerical approximation techniques, 
described more fully later in this chapter, and the Microsoft Excel spreadsheet. 
Computer simulations of the spread of hepatitis C through the IDU population will be 
perfonned. These will concentrate on providing estimates oft he prevalence of hepatitis 
C in the drug using community of Penh, Western Australian as they move from one 
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subgroup to another (susceptible to infectious, infectious to removals) using varying IDU 
population denominators. 
Once a comprehensive model has been developed it can then be refined to include 
accurate estimates of injecting drug users, who in 20 years time fall into the susceptible, 
infectious or removals categories. This information will then be used to estimate the cost 
of treating those persons with active HCY infection and those with cirrhosis or HCC. 
3.2.1 Model I 
The initial model is designed to simulate a simple rate of needle sharing model, where 
gender di!Terenccs and length of use arc not considered. An important di!Ten:ncc 
between the models described below and previous work done on lilY/AIDS transmission 
using SIR models is the interaction between susccptibles, infectious and removals. 
While development of cirrhosi!': is judged to be the transition point to '.he remov:i.ls 
category, many individuals in this group remain asymptomatic for many years and will 
continue to inject drugs and interact with individuaJs in the other two groups. 
This basic model is: 
X(l) the numb1..'1" of inj(.cting drug users susceptible to contracting hepatitis C, 
Y(t) the nund>cr of injecting drug users infected with hepatitis C, 
A(l) the number of injecting drug users with cirrhosis of the liver or hepatocellular 
carcinoma, and 
P(t) the total population of injecting drug users 
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elY(/) ~~~~X(I/(1) + A(l) (Jl+a)Y(/) 
dl 1'(1) 
dA(t) ~ aY(I)- (po)A(t) 
dt 
1'(1) X(l} I Y(l) I A(l} 
where 
A= the recruitment rate to the lOU population 
_!_ =the mean incubation period for hepatitis C 
<l 
6 =the cirrhosis/hepatocellular carcinoma related death rate 
~ =the migration rate out oft he population 
" P =the probability of transmission during a single needle sharing act 
n =the rate of needle sharing per unit time 
3.2.2 Model 2. 
This second model incorporates the major transmission factor: -length of time engaged 
in injecting drug use. Four groups have been established where group I consists of those 
injecting for less than five years, group 2 those injecting for S-9 years, group 3 those 
injecting for 10-1 5 years and group 4 those injecting for greater than 15 years. Groups 
ure identified by the subscripts I to 4, where X1(t) represents the number of susceptible 
individuals in group 1 at timet. 
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This model also has those in the removals category continuing to mix with those who are 
susceptible or infectious. The groupings reflect length of time an individual has been 
engaged in injecting drugs and given the nature of their interactions with other lOU's, 
they are equally likely to be mixing with mdividuals of other groups. A person who has 
been injecting drugs for three years has an equally likely chance of interacting with 
others who have been injecting for eight, ten or fifteen years, especially if their lifestyle 
has marginaliscd them from society. As such the model reflects this likelihood of an 
individual, i.e. X 1(1) having the opportunity of sharing injecting equipment from all other 
infectious and removals. 
lbe model, when simulated, has monthly iterations. Thus for a twenty year projection, 
240 iterations are performed. To reflect this monthly simulation, the movement through 
the susceptible, infectious, and removals categories are also incremented monthly, reflect 
by the proportion, -
1 
. 
60 
This model now becomes: 
dX, (I) = A -npX (1/(1) + A(l) )!X, (I)- 610 X, (I) 
dl ' 1'(1) 
dX,(I) = -npx" (I) Y(l) + A(l)- )!X (I)+ _I (X (I)- X (I)) 
dt 2 P(t) 2 60 1 2 
dX, (1) = -npx" (1) Y(l) +A (I)- "v (I)+ _I (X (I)- X (I)) 
dt 3 P(t) '"""' 3 60 2 1 
dX,(I) =-npx" (I)Y(I)+A(I) _ .. v (l)+-1 X (I) 
dl ' 1'(1) >"'' 60 ' 
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dY, (I) " 11~ (l/(1) +A( I) 
dl ' 1'(1) 
I (1.1+ a)~ (I)--~ (I) 
60 
dY,(I) " 11~,(l) Y(l)+ A(l) 
dl - 1'(1) 
I (~ +a)Y, (I)+-(~ (I)- r, (I)) 
60 
dY,(I) "11PX (1/(l) +A(:)-(~+ a)Y (I)+ -1 (Y (I)- Y (I)) 
dt 1 P(t) .l 60 2 1 
dY, (I) "nPX u/(1) + A(l) 
dl ' 1'(1) 
I (~+a)Y,(I)+ 
60 
1';(1) 
dA (1) I 
-'- "a~(1)-(~ +B)A,(I)--A,(I) 
dl 60 
dA,(I) "nY,(I)-(~+B)A,(I)+-1 (A,(I)-A,(I)) 
dl 60 
dA (I) I 
-'-" aY,(I)- (~ +B)A,(I) +-(A,(I)- A,(l)) 
dl 60 
dA (I) I 
-'- "aY,(I)- I~ +B)A,(I) +-A,(I) dl . 60 
• 1'(1) ~ ~ {X,(I) I Y,(l) I A,(l}) 
•~J 
where 
A = the recruitment rate to the IOU population 
_!_ =the mean incubation period for hepatitis C 
a 
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6 = the cirrhosis/hepatocellular carcinoma related death rate 
J.l =the migration rate out of the population 
p =the probability of transmission during a single needle sharing act 
n = the rate of needle sharing per unit time 
3.3 Numerical Approximation Techniques: 
3.2.1 Euler's Method. 
Euler's Method (Gerald and Wheatley) is a numerical technique that employs the first 
two terms of the Taylor-series 
y(x) c y(xa) 1 y' (xa)(x- xa) 1 y"(xo) (;x-x-'1 + y"'(xo) J 2! " 31 (x-xa) I ...... . 
to approximate the solution to first order differential equations. This method relies on 
the step size h being small enough to allow truncation of the Taylor-series after the first 
derivative tenn. This gives 
"(~)h' y(x0 + h) -- y(xa) 1 h y' (xa) 1 "--y -=::.... 
2 
xo<~<xo+h 
(~error term) 
Here y(xq) is given by the initial condition and y' (xa) is evaluated from j(xo.ya) given by 
the differential equation, dy!dx --j(x,y). This method is an iterative method, advancing 
the solution, y(xo + h), y(x1 ' h), y(x2 ' h) etc. 
The algorithm for Euler's Method may be expressed: 
Yn•J = Yn I· hy',. I O(/?} (O(h') the local error) 
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A major limitation ofE!der's method in approximating first order differential equations 
is, unless the step is extremely small it lacks accuracy (see Figure 4). 
--·---·---··---------·-· ! ....._,__ 
! 
Figure 4. Lac:kofaccuracy of Euler's Method. 
3.3.2 Modified Euler's Method. 
slope at Xt computed with Xt,YI 
(from Euler) 
True Y1 value 
In order i.O calculate the correct average slope between Yn and Yn+ 1 it is necessary to 
calculate the mean of the slopes at both ends of the interval. This could be done by using 
Y' +y' Y ~y+h""fl Itt/ If 2 
Unfortunately it is not possible to evaluate i n+l when Yn+ 1 is unknown. The modified 
Euler method overcomes this by estimating a value of Yn·+ 1 using Eulers method (3.3.1) 
and then using this value to computey' 1t+l giving an improved value for J11+J. 
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3.4. Computational Methods. 
3.4.1 Modell Using Eulers Method. 
The model was approximated with Euler's Method using Excel vS.O for Windows. 
Parameters used were: 
Lambda 
n 
betahat 
x(O) 
y(O) 
mu 
alpha 
delta 
a(O) 
hx 
hy 
ha 
the recruitment rate to the IOU population {per month) 
the rate of needle sharing per unit time (per month) 
the probability of transmission per act of needle sharing 
the number oflDU susceptiblcs at the start of the simulation 
the number ofiDU infectious at the start of the simulation 
migration rate out of the population (per month) 
1/alpha =mean incubation period (in months) 
death rate due to HCC/cirrhosis (per month) 
number of lDU cirrhosis/HCC cases at start of simulation 
step for x 
step fory 
step for a. 
hx, by and ha all represent the step increment of the Eulers model. To distinguish 
between the theoretical model and the computational model, now x(O) -- X(O), the initial 
number of susceptibles at time, t --- 0. 
The computations for the model involved the following steps: 
x Iteration I: ~ x(O) 
Iteration j~: =x 1_1 + (x'1_1 *hx) 
Page 68 
y Iteration 1: = y(O) 
a Iteration I: = a(O) 
Iterationj:<!:2: =a1_1 +(a1_1 *ha) 
p Iteration 1: = x1 + y1 + a1 
x' I 
Y} 
a' J 
=/ambda-(n'betahat•x1'({yj+ap!p,J}-(mu'x) 
={n'betahat•x1•((y1+a,Jip)-((mu+a/pha)'y,J 
=(alpha'y)-((mu+delta)'a) 
3.4.2 Modell and Modified Euler's Method. 
The model was approximated with the modified Euler's method using Excel v5,0 for 
Windows. Parameters used were: 
Lambda the recruitment rate to the IDU population (per month) 
n the rate of needle sharing per unit time (per month) 
betahat the probability of transmission per act of needle sharing 
x(O) the number ofiDU susceptibles at the start ofthe simulation 
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y(O) the number of IOU infectious at the start of the simulation 
mu migration rate out of the population (per month) 
alpha 1/alpha =mean incubation period (in months) 
delta death rate due to HCC/cirrhosis (per month) 
a(O) number ofiDU cirrhosis/HCC cases at start of simulation 
hx step for x 
by step fory 
ha step for a. 
hx, hy and ha all represent the step increment of the Euler's model 
The computations for the model involved the following steps: 
X Iteration 1: ~ x(O} 
Iteration j0>2: ~ x1.1 1 (hx*((k/1 k2)12) 
newx Iterationj: newx1 ,~ xrl-(hx*kl) 
y Iteration 1: ~ y(O} 
Iteration j0>2: ~ y1.1 1 (hy'((k3+k4)12)) 
newy lterationj: newy1 Yrl-{hy*k3) 
a Iteration 1: ~ a(O} 
Iteration j0>2: ~a1. 1 1 (ha'((k51 k6)12)) 
newa Iteration j: 
p lterationj 
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newp 
x' I 
a' I 
kl: 
k2: 
k3 
k4 
kS 
k6 
Iterationj 
Iterationj 
Iterationj 
lterationj 
lterationj 
Iterationj 
Iteration j 
~ lambda-(n *bet aha/ *x1 *( (y1 1 a;)lp) )-(mu*x) 
= lambda-(n*betahat*newx1*((newy1+newa)lnewp.J-
(mu*newx.J 
- (n*betahat *x1*((y1 •a)lp))-((mu+alpha) *y) 
=(u*betahat*llewx1*((newy1 1 newa.J!newp.J)-
((mu •alpha)*newy) 
-(alpha*y)-((mu 1 delta) *a) 
--(a/pha*newy)-((mu I delta)*newa) 
3.4.3 Model2 and Euler's Method. 
This was the first simulation of hepatitis C transmission using length of injecting drug 
use. As we saw in Chapter 2, persons infected with hepatitis C are not diagnosed with 
cirrhosis of the liver or hepatocellular carcinoma less than 15 years after commencing 
injecting. For this reason, only one group is used for those in the removals category, 
namely a4. The model was approximated with Euler's method using Excel vS.O for 
Windows. Parameters used were: 
Lambda the recruitment rate to the IOU population (per month) 
n the rate of needle sharing per unit time (per month) 
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betahat 
xi(O) 
x2(0) 
x3(0) 
x4(0) 
yi(O) 
y2(0) 
y3(0) 
y4(0) 
p(O) 
mu 
alpha 
delta 
a4(0) 
hx 
hy 
ha 
the probability of transmission per act of needle sharing 
number oflDU susceptibles at start of simulation using 0-4 yrs 
number oflDU susccptibles at start of simulation using 5-9 yrs 
number ofiDU susceptibles at start of simulation using 10-14 ys 
number of IDU susceptibles at start of simulation using 15+ yrs 
number of IOU infectious at start of simulation using 0-4 yrs 
number of IOU infectious at start of simulation using 5-9 yrs 
number ofiDU infectious at start of simulation using 10-14 yrs 
number of IOU infectious at start of simulation using 15+ yrs 
Total number ofiVDU's at start of simulation 
migration rate out of the population (per month) 
1/alpha =mean incubation period (in months) 
death rate due to HCC/cirrhosis (per month) 
number of IOU cirrhosis!HCC cases at start of simulation using I 5+ years 
step forx 
step fory 
step for a. 
hx, by and ha all represent the step increment of the Euler's model. 
The computations for the model involved the following steps: 
xi Iteration!: ~xl(O) 
lterationj2:2: =x1j.J !-(x1'1•1*hx) 
x2 Iteration I: ~ x2(0} 
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x3 
x4 
X 
yl 
y2 
y3 
y4 
y 
a4 
Pi 
Iteration j;;:a: = x21.J_,_ ( x2'J-I *hx) 
Iteration I: = x3(0) 
Iterationj;;:a: =x31.J t (x3'1-J*hx) 
Iteration 1 : =x4(0) 
Iteration j~: =x41.1 t (x4'1.1*hx) 
Iteration 1: x, '' xl {0) 1 x2{0) 1 x3(0) 1 x4(0) 
Iterationj~: Xj ·"' Xlj ·l x2; I X3j + X4j 
Iteration 1 : = yi{O) 
Iteration j~: = y11.1' (yl'r1*hy) 
Iteration I: = y2(0) 
Iteration j~: = y2J,,, (y2'J-1'hy) 
Iteration 1: = y3(0) 
Iteration j~2: = y3J-I I (y3'J-1'hy) 
Iteration I: = y4(0) 
Iteration j~: = y4J-I I (y4'!-l'hy) 
Iteration 1: Y1 • yi{O) I y2{0) I y3{0) I y4(0) 
Iteration j~: Y, ~- ylj 1- y21 I y31 I y41 
Iteration I : = a4(0) 
lterationj~: =a41.J·t(a4'r,*ha) 
Iteration j 
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xl' Iteration j ~ lamhdn-(n'betahat'xl i '((y1 1 a)lp))-(mu'xl )-I/60'xl1 
x2' Iteration j ~ -(n'betahat'xZ, '((y, • a)ip))-(mu'x2) 1 (J/60'(xlrx2)} 
x3' Iteration j = -(,•betahat*x31 *((y1 + a)'p))-(mu*x3J r ( J/fiO*(x2rx3)) 
x4' Iteration j ~ -(n'betahat'x41 '((y, • a)•P)}-(mu'x4) • (1160'x3) 
yl' Iteration j ~ (n'betabat'x IJ"((y, • a)ip)}-((mu • alpha} 'yl) - /!60'yl1 
y2' Iteration j = (n*hetahat*x21 *((y1 + a)/p))-((mu+ alpha)*y2J • (1!60'(yl, -y2)} 
y3' Iteration j := (n*hetahat*x31 *({)J + a).p))-((mll +alpha) *yJ) + (1•611'(y2rY.1)} 
y4' Iteration j (n'betahat'x4J"((y1 • a)p)}-((mu • alpha)'y4) • (1160'y3) 
a4' Iteration j ~ (alpha'y4)-((mu • delta) 'a4) 
3.4.4 Modcl2 and Modified Euler's Method. 
Once again because persons infected with hepatitis C are not diagnosed with cirrhosis of 
the liver or hepatocellular carcinoma less than IS years after commencing injecting only 
one group is used for those in the removals category, namely a4. The model was 
approximated with modified Euler's Method using Excel vS.O for Windows. Parameters 
used were: 
Lambda 
n 
betahat 
the recruitment rate to the IOU population (per month) 
the rate of needle sharing per unit time (per month) 
the probability of transmission per act of needle sharing 
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xl(O) number of IOU susceptiblcs at start of simulation using 0-4 yrs 
x2(0) number of IDU susccptibles at stan of simulation using 5-9 yrs 
x3(0) number of IDU susccptiblcs at start of simulation using 10-14 ys 
x4(0) number of IOU susccptiblcs at start of simulation using 15+ yrs 
y 1(0) number of IDU infectious at start of simulation using 0-4 yrs 
y2(0) number of IOU infectious at start of simulation using 5-9 yrs 
y3(0) number oflDU infectious at start of simulation using 10-14 yrs 
y4(0) number of IOU infectious at start of simulation using 15 t- yrs 
p(O) Total number ofiVDU 's at !.1art of simulation 
mu migration rate out of the population (per month) 
alpha 1/a\pha = mean incubation period (in months) 
delta death rate due to HCC/Cirrhosis (per month) 
a4(0) number of IDU Cirrhosis/HCC cases at start of simulation using 15+ years 
hx step for x 
hy Slep for y 
ha step for a. 
hx. hy and ha all represent the step increment of the Euler's model. 
The computations for the model involved the following steps: 
xl Iteration I: o xi(O) 
Iteration j22: o xl1., • (hx'((k111 • k21)12) 
newxl Iteration j: 
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x2 Iteration J : =x2(0) 
Iteration j~2: = X2j./ ! (hr•((k121 I k22)!2) 
ncwx2 Iteration j: newx2j :a x2i' (hx•kf 2) 
x3 Iteration I : = x3(0) 
Iteration j~: = X31.f t (hr*((k) 31 I k23)/2) 
newx3 Iteration j: ncwx3; = x31 1 (hx*kl3) 
x4 Iteration I : = x4(0} 
Iteration j;;,:2: = x41., i fhx*((kt41 11a.4,J12; 
newx.4 Iteration j: newx4i = x41 1 (hx•k14.J 
xi ···x1{0) t x2(0) 1 x3(0) 1 x4(0) 
x1 "' xl1 , x21 1 x31 t x41 
newx1 - newxl1 -1 newx21 1 newx31 + newx41 
yl 
ncwyt 
y2 
newy2 
yJ 
Iteration I: = yl{O) 
Iteration j;;,:2: --= y11.1 1 (hy•((k31, t k4 l)ll} 
Iteration j: newyl j = yl1 1 (hy*k3 l) 
Iteration I: = y2(0) 
Iteration j;.-:2: = y').1.1 1 (hy*((k321 1 k42.Jl2} 
Iteration j: ncwy2j = y21 1 (hy*k32) 
Iteration 1: = y3{0} 
Iteration j;..:2: = y31., t (hy•((k.331 1 k43.Jll} 
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newy3 Iteration j: ncwy3; ~ y31 1 (hy'k33) 
y4 Iteration 1: ~ y4(0} 
Iteration j>2: ~ y41•1 1 (hy'((k341 1 k44)12) 
newy4 Iteration j: ncwy4; ~ y41 1 (hy'k34) 
Y1 yl(O) I y2(0} I y3(0) I y4(0) 
YJ •:_ ylj l y2J + y3J ! y4; 
newy1 -- newyl1 ! newy21 + neH-y31 + new}r41 
a4 
newa4 
P; 
ncwp 
rl' kll 
k21 
Iteration 1: = a4(0) 
Iteration j>2: ~ a411 1 (ha'((k541 1 k64)12) 
Iteration j: 
Iteration j 
ltt,-ation j 
Iteration j 
Iteration j 
ncwa41 :::: a41 1 (ha*/c54) 
""lamhda-(n*betahat'xl/({y1 1 a.J.p))-(mu•xt) 
._,.lambda -(n*ht·tahat'newxlJ'(new:/llewp))-
(mu•newxl)- (1 60'nt•wrl) 
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x2' k12 Iteration j ~ -(n*belahal*x2J"((y1 1 a)!p))-(mu 'x2) 1 
(1/60 *(xlr x2)) 
k22 Iteration j = -(n *hetahat*(newx2) *(newzjnewp;)) -
(mu*newx2) t (1!60*(newx11 -newXZ)) 
x3' k13 Iteration j ~ -(n*belahal*x3J"((y1 1 a)lp))-(mu*x3) 1 
(1160'(x21 -x3)) 
k23 Iteration j = -(n*hetahat*newx3) *(newzjnewp))-
(mu*newx3) t (/!60*(newx21 -newx3) 
x4' k14 Iteration j ""-(n*hetahat*x41 *({>] + a),i1))-(mu*x4) t (/!60*x3) 
k24 Iteration j = -(n*betahat *newx4.J *(newzjne""1'))-
(mu*newx4) + (J;60*newx3) 
yl' k31 Iteration j ~ (n*be/ahal*xl/({y1 1 a)IJJ)I-((mul a/pha)*yl)-
(/160*yl) 
k41 Iteration j = (n*hetahat*newxl 1 *(newzjnewp))-
((mu 1 alpha)'(newyl))- (/!60'newyl) 
y2' k32 Iteration j = (rr*be/ahal'x21 *((y1 1 a)lp))-((mul alpha) 'y2) I (/160 
'(ylry2) 
k42 Iteration j = (n*betahat*newx21 *(newzjnewp))-((mu t alpha) 
*(newy2)) 1 (1160*(newyl1 - newy2) 
y3' k33 lten:llionj = (n'helahal*x31 *((y1 1 a)lp))-((m111 alpha)*y3) 1 (1160 
*(y2) -y3) 
k43 lterationj = (n*hetahat*newx31 *(newzjnewp)}-
((mu I alpha)'(newy3)) I (1160*(newy21- rrewy3)) 
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y4' k34 Iteration j ~ (n'hetahot'x~'((y11 a)lp))-((mu 1 alpha) 'y4) 
1(//60'y3) 
k44 Iteration j = (n*hetahat•newx4i*(newzJnewp))-
((mu 1 a/pha)'(newy4)) 1 (1160'newy3) 
a4' k54 Iteration j ~ (alpha'y4)-{{mul delta)'a4) 
k64 ltcrationj = (a/fJha*newy4)-({mul della) *newa4) 
To summarise, two models were developed using two approximation techniques. The 
Euler 1 model produces results equivalent to those produced by Euler 2 (the model 
incorporating length of drug usc). The modified Euler's model I also produces result 
equivalent to the modified Euler's 2 model (the model incorporating length of drug use). 
This is expected as the same parameters were used to test all four models. There is a 
slight difference in results between the Euler models and the modified Euler's models, 
this being due to rounding. All further work was carried out using the modified Euler's 
method incorporating length of injecting drug use. 
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MODEL PARAMETERS 
4.1 Population Sizes. 
The model requires estimations of the number of persons in each risk group. These 
estimations will be based to a large extent on the population numbers of Western 
Australia. In 2001 (the last census year}, the distribution of the Western Australian 
population, in five year age groups was as defined by Figure 5. 
Population of Western Australia, 2001 ~ Mlle 
---Female 
80000 .....-----------------------'=====---' 
7CXXlO t-:;;;!'.~::a~ --=~~===-~=-----------
tll 60000 +."'------=------_____J,...____ _________ _ 
a 
f50000 +---------------'-----------
:. 040000 +--------------~_,_ ________ _ 
j 30000 -t-------------------'=,,;;;::.;;.-------
§ 20000 +-----------------_.,,.,_~ -----
z 
1CXXlO +--------------------"k---'.,....---
o -l-~~~~~-~~~~~~~-~~~~~.=::~~ .......... 
Age Group 
Figure 5. Population of Western Australia in 2001 by age group and gender. 
Source: Cdata2001 
The population groups to be incorporated into the model are those aged 15 to 49 years, as 
seen in Chapter 2, these age groups represent those most at risk of HCV through 
injecting drug use. In 2001, 51.5% of the Western Australian population or 943,653 
persons were in this category (see table 30). Proportionately, Western Australia has 
9. 8% of the national population. 
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Given an estimated 150,000 to 200,000 intravenous drug users in Australia (Hulse, 1993; 
Wodak, 1994; Wodak, 1995; Wodak, 1997; Crofts, 2001), the number ofiVDUs in 
Western Australia can be approximated to 14,700 to 19,600 persons. 
Age group 
15_19 
20 24 
25 29 
30 34 
35 39 
40 44 
45 49 
Grand Total 
Female 
66,4\3 
60,736 
63,711 
69,4\3 
71,750 
72,363 
67,467 
471,853 
Male 
69,866 
63,257 
64,084 
68,360 
69,806 
70,491 
65,936 
471,800 
Total population 
\36,279 
123,993 
127,795 
137,773 
141,556 
142,854 
133,403 
943,653 
Estimated number of 
IVDUs ioWA 
2,123 to 2,831 
1,932 to 2,575 
1,991 to 2,654 
2,146 to 2,862 
2,205 to 2, 940 
2,225 to 2,967 
2,078 to 2,771 
14,700to 19,600 
Table 30. Number of persons in each age group by gender in 2001. Source for 
population data: Cdata200t. 
Croft ( 1993) produced results of a cohort of intravenous drug users showing age and 
duration of use. Use the same percentages (table 30) the number of Western Austra1ian 
intravenous drug users by duration of use is shown in table 31. 
-------;~;------...,-:-:--;;-----pop-14,700 pop='l9,b~,_o __ 
0-4years 
5-9 years 
10-14 years 
15+ years 
total 
3,844 5,125 
3,196 4,260 
2,800 3,734 
4,860 6,480 
14,700 19,600 
Table 31. Estimated number of intravenous drug users in Western Australia by 
duration of use. 
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4.2 Number of IVDU ci"hosis/HCC Cases. 
Literature suggests that approximately 20% of all cases ofHCV (Crofts, 200 I; Dorc ct. 
al. 2002; Freeman ct. al. 2003; Law et. aJ. 2003.), develop cirrhosis over a 20 year period. 
This means that only those injecting for more than 15 years are eligible for inclusion in 
this category. The estimated number oflVDUs with cirrhosis or HCC are given below. 
cirrhosis cirrhosis 
(~·~ ~ 14700) (~op ~ 19600) 
04 0 0 
S-9 0 0 
10-14 0 0 
IS+ 972 1296 
Table 32. Estimated number of intravenous drug usen with cirrhosis/HCC by 
duration of use in 2001. 
4.3 Number of IVDU's with hepaJitis C vin~s Infection. 
Hepatitis Cis a notifiable disease. The 1999 HIV/AIDS, Hepatitis C& Sexually 
Transmissible Infections in Australia: Annual Surveillance Report shows Western 
Australia had 4,502 new cases of hepatitis C infection in 1998 at a rate of98.7 per 
100,000. Literature suggests the incidence of hepatitis C among injecting drug users to 
be between 7% and 15% per year, (Mather and Crofts, 1999; Law, 1999; Crofts, 2001; 
Law et. al. 2003, Murray, et. al. 2003). As intravenous drug usc is now acknowledged to 
be responsible for 75 to 85% of all new hepatitis C infections in Australia. this translates 
to between 3376 and 3827 new case of hepatitis C infection in Western Australia for 
1998 due to intravenous drug use. 
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According to the 1999 HI VI AIDS, Hepatitis C & Sexually Transmissible Infections in 
Australia: Annual Surveillance Report, 1 ?0/o oflVDU's injecting for less than 3 years 
were infected with the HCV virus nationally. Among those injecting for 3-5 years, zgofo 
were infected and 69% infected among those injecting for 6 years or more. These figures 
are lower than those published by Crofts (1993) where he shows an infection rate of 
38.6% for those injecting 0-4 years, a 70.9% infection rate for those injecting for 5-9 
years, a 90% infection rate for those injecting for 10-14 years and 90.5% infected when 
injecting for 15 years or more. The 1999 HIV/ AIDS, Hepatitis C & Sexually 
Transmissible Infections in Australia does not use the same age categories as those used 
by Crofts, however estimations will 0e made using these lower infection percentages to 
form a lower boundary, while the results of Crofts will be used as an upper boundary. 
Adjusting for the numbe.r of estimated cases with cirrhosis/HCC, we get: 
ToW 
0-4 
S-9 
10-14 
IS+ 
Total 
infected 
op ~ 14,700) 
Lower ~ 
654 1,484 
2,205 2,266 
1,932 2,520 
2,381 3,450 
7,121 9,668 
infected 
(pop ~19,600) 
Lower ~ 
871 1,978 
2,940 3,021 
2,576 3,360 
3,175 4,601 
9,563 12,961 
Table 33. Estimated number of intravenous drug users infected with the hepatitis C 
virus by duration of use in 2001. 
4.4 Number ofiVDU's thaJ do not have the hepatitis C virus. 
After subtracting those who are infectious or have cirrhosis/HCC from the IVDU 
population we get: 
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Total 
0-4 
5-9 
10-14 
15+ 
Total 
not infected 
(pop= 14,700) 
Lower ~ 
3,191 2,360 
991 930 
868 280 
1,507 437 
6,533 3,986 
not infected 
(pop =19,600) 
Lower ~ 
4,254 3,147 
1,321 1,240 
1,157 373 
2,009 583 
8,741 5,343 
Table 34. Estimated number of intravenous drug users not infected with the 
hepatitis C virus by duration of use in 2001. 
4. 5 Recruitment and Migration Rates. 
No published material was available on the recruitment rate to the IVDU population. 
Murray (2003) estimates the rate of increase among IDU's in Australia was 7% until 
I9n and 5% thereafter. Varying rates will be used with 7% as an upper bound for the 
mod~~ given that the rates used by Murray are estimates. 
If recruitment rates oft%, 3%, 5% and 7% of the existing IVDU population are 
0 
considered we get: 
pop 14,700 
pop= 19,600 
1% 
147 
196 
3% 
441 
588 
735 
980 
7% 
1,029 
1,372 
Table 35. Estimated number of persons recruited to the IVDU per annum. 
As the model currently estimates a monthly change all the above will be divided by 12. 
For the lack of any published materia~ it will be assumed that the migration rate out of 
the IVDU population will match the recruitment rate (for example, at a rate of3%, the 
migration rate will equal 0.03/12 per month). 
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4.6 Rate of Needle Sharing per Unit Time 
The 1999 HIV/AIDS, Hepatitis C & Sexually Transmissible Infections in Australia: 
Annual Surveillance Report indicates that 15% oflVDU's injecting in the past month 
and using for less than three years, shared needles and syringes. Likewise 14% of those 
using for three years or more and injecting in the last month shared needles and syringes. 
Thus if 15% of users share needles and syringes we have a rate of0.15. 
Total 
0-4 
5-9 
10-14 
IS+ 
0At sharing needles and 
syringes 
IS 
14 
14 
14 
Table 36: Rate of needle sharing per month. 
Rate or needle sharing 
per month. 
0.1.5 
0.14 
0.14 
0.14 
4. 7 Probability ofTransmi~ion During a Single Needle Sharing Act 
Crofts, Aitken and Kaldor (1999) estimated the probability of infection with HCV from a 
needle sharing act was 1.3 to 4.9 (divided by 1 00). This estimate is consistent with an 
editorial by Watson (2000) where the risk of transmission by an individual needle stick is 
upto6.1%. 
4. 8 Death Rate Due to hepatocellular cardnomolci"hosis. 
The number of people at risk of dying from hepatocellular carcinoma or cirrhosis are 
drawn from the population injecting for fifteen years or more. Literature suggests that I 0 
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years after a diagnosis of Cirrhosis, 75% were experiPI'lcing severe symptoms (Yano M 
et. al., 1996). 
By calculating the proportion of persons with severe symptoms after 10 years and 
dividing by 12 to obtain a rate per month, the death rate due to hepatocellular carcinoma 
or cirrhosis is 0.00625. 
Page 86 
SIMULATION RESULTS 
5.1 Totallntraveno!As Drug Using population, 14,700 
Parameters that will remain constant are 1) the mean incubation rate of six weeks results 
in a value of 0.6 [ ...!_ = -1-] and, 2) the rate in which hepatitis C progresses to cirrhosis. 
a 1.5 
Evidence suggests a time span of20 to 30 years, therefore the average of25 years will be 
used resulting in a value of o.oo) [ B = --1-(25*12months)]. 
300 
The probability ofinfcction from a single needle sharing act is made up of two 
parameters, the rate of needle sharing per unit time (0.14) x probability of infection 
during a single needle sharing act. Crofts, Aitken and Kaldor estimated this to be 1.3 to 
4.9, giving a low probability of infection from a single needle sharing act of0.182 and a 
high probability of0.686. 
5.1.1 Population 14,700 with low infectivity rates and a low probability of infection 
from a single needle sharing act. 
Using the rates of infection supplied by the 1999 HIV/AIDS, Hepatitis C & Sexually 
Transmissible Infections in Australia: Annual Surveillance report population numbers are 
as follows: 
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0-4 years 5-9 years 10-14 15+ years 
IVDU's that do not have HCV, X(t) 
IVDU's who do have HCV, Y(t) 
IVDU's with cirrhosis/HCC, A(t) 
Rate of needle sharing per month, (n) 
Parameters 
1% recruitment rate, (A) 
3,191 
654 
0 
0.15 
991 
2,154 
0 
0.14 
Probability of transmission during single needle sharing act (P) 
(Rate of needle sbaring*probability of infection) 
Migration rate out ofIVDU population,(µ) 
Mean incubation rate - 6 weeks, ( _!_) 
a 
Death rate due to HCC/cirrhosis 
Rate at which hepatitis C develops into cirrhosis 
ears 
868 
1,932 
0 
0.14 
Table 37. Parameters: Population 14,700, low infectivity rates and a low 
probability of infection from a single needle sharing act. 
1,507 
2,381 
972 
0.14 
147 
0.182 
1% 
0.6 
0.00625 
0.003 
Using model 2 developed in Chapter 3 and the parameters described in Table 37, with 
initial conditions also in Table 37, we can provide the following output from the 
simulations. 
Number of susceptibles, X(t) 
7000 
Total Susceptible 
- 0-4years 
- ~years 
- 10-14 years 
~ 15+ years 
~ ~ ~ ~ ~ ~ ~ ~ ~ e B 8 ~ ~ m ~ ~ ~ ~ ~ ~ 
Number of months 
Figure 6. Number of susceptibles after 20 years, population 14,700, low inf ectivity 
rates and a low probability of infection from a single needle sharing act. 
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Figure 6 clearly illustrates a decline in the total susceptible population, with those in the 
0 - 4 years injecting group in most rapid decline and those in the 10-14 years injecting 
group is the slowest. The population of susceptible IDU's is reduced by 50% after 74 
months. 
• C 
0 
~ 
! 
-0 
... 
1l 
E 
:I 
z 
10000 
9000 
8000 
7000 
6000 
5000 
4000 
3000 
Number of infectious, Y(t) - 0-4years 
5-9 years 
- 10-14years 
-+ 15+yeers 
- Total nfectious 
: .,;._...,..,..--------------------
- ~ ~ ~ ~ w ~ ~ ~ ~ ~ 8 ~ ~ m m ~ ~ ~ ~ ~ 
Number of months 
Figure 7. Number of infectious after 20 years, population 14,700, low infectivity 
rates and a low probability of infection from a single needle sharing act. 
Figure 7 indicates an increase in the number of infectious individuals, as those who are 
susceptible move into this category. The numbers increase steadily for 124 months and 
then start to decrease. The greatest movement comes from those individuals who have 
been injecting for 15 years or more. 
Figure 8 shows a steady increase in the number of individuals moving into the removals 
category. The number of persons with cirrhosis or HCC doubles after 160 months. 
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2700 
2400 
• 2100 
C 
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Figure 8. Number of removals after 20 years, population 14,700, low infectivity 
rates and a low probability of infection from a single needle sharing act. 
In this situation, where the lower infectivity rates are used, after 20 years this IVDU 
population now numbers 12,337, with 946 not infected, but at risk, 8,889 infected and 
still needle sharing and with 2,502 persons having severe cirrhosis or HCC. 
Using the same initial population numbers and probability of infection, the table below 
gives results based on recruitment and migration rates of 3%, 5% and 7%. 
Recruitment Migration Susceptibles Infectious Removed Total 
Rate Rate X(t) Y(t) A(t) 
3% 3% 2,426 8,838 1,814 13,078 
5% 5% 3,884 8,383 1,318 13,585 
7% 7% 5,299 7,677 958 13,935 
Table 38. Number of susceptible, infectious and removals after 20 years with 
varying recruitment and migration rates. 
As the recruitment rate increases among this cohort the number of susceptible IVDU' s 
increases. The corresponding migration rate show a movement out of the drug using 
Page 90 
population and a smaller number of people suffering ill effects from cirrhosis and 
hepatocellular carcinoma. 
5 .1.2 Population 14, 700 with low infectivity rates and a high probability of infection 
from a single needle sharing act. 
Consideration will now be given to population number where the probability of infection 
during a single needle sharing act is 0.686. Initial recruitment and migration rates will be 
set at 1 % and the other parameters and population numbers will be unchanged. 
7000 
6500 
6000 
• 5500 
~ 5000 
! 4500 
8_ 4000 
... 3500 0 
~ 3000 
.! 2500 E 
:, 2000 
z 1500 
1000 
500 
0 
Number of susceptibles, X(t) 
..... ~ IC) N 
Number of months 
Total Susceptible 
- 0-4years 
- ~years 
- 10-14 years 
- 15+years 
Figure 9. Number of susceptibles after 20 years, population 14,700, low infectivity 
rates and a high probability of infection from a single needle sharing act. 
Figure 9 illustrates a rapid decline in the total susceptible population, with those in the O -
4 years injecting group in most rapid decline and those in the 10-14 years injecting group 
is the slowest. The population of susceptible IDU's is reduced by 500/o after only 18 
months. The higher probability of infection results in a rapid shift from the susceptible 
group into the infected population. 
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Figure 10. Number of infectious after 20 years, population 14,700, low inf ectivity 
rates and a high probability of infection from a single needle sharing act. 
There is an initial rapid rise in those infected followed by a decrease as they move into 
the cohort affected by cirrhosis and HCC. The number of infectious individuals peaks at 
60 months (n = 12,461) and slowly decreases thereafter. 
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Figure 11. Number of removals after 20 years, population 14,700, low infectivity 
rates and a high probability of infection from a single needle sharing act. 
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Using the same initial population numbers and high probability of infection !Tom a single 
needle sharing act, the table below gives results based on recruitment and migration rates 
of3%, 5% and 7%. 
~--;,--,--~c-----
Recruitment Migration Susceptibles Infectious Removed Total 
Rllte ___ Rll~ ----~(t)_ ___ TI!l ____ A{,t~)~-
3% 3% 577 10,392 1,947 12,916 
5% 5% 963 11,037 1,456 13,456 
~~_.7coo/,:C' -o;- _ _ _2~·- _l,l_~ll__ __ II , 381 _____ 1, 100 __ _ 1!, 829 __ 
Table 39. Number of susceptible, infectious and removals after 20 years with 
varying rr<:ruitment and migration rates. 
The higher the recruitment rate the higher the number in the needle sharing but not 
infected cohort becomes. However, as the number of infectious increases this is due 
solely to weight of numbers rather than behaviour changes. Thus the infection rate 
appears to be a key parameter from a IICV control policy viewpoint. The increase in the 
number of infected persons is not great and rcOccts the number leaving intravenous drug 
usc prior to infection. The number of persons with cirrhosis/HCC, however docs 
decrease, indicative once again of people leaving before becoming infected with hepatitis 
c. 
5.1.3 Population 14,700 with high infectivity rates and a low probability of infection 
!Tom a single needle sharing act. 
Using the rates of infection supplied by Crofts ( 1993) population numbers are as follows: 
Page 93 
0-4 years 5-9 years 
IVDU's that do not have HCV, X(t) 
IVDU's who do have HCV, Y(t) 
IVDU's with cirrhosis/HCC, A(t) 
Rate of needle sharing per month, (n) 
Parameters 
1% recruitment rate, (A) 
2,360 
1,484 
0 
0.15 
930 
2,213 
0 
0.14 
Probability of transmission during single needle sharing act (P) 
(Rate of needle sharing*probability of infection) 
Migration rate out ofIVDU population,(µ) 
Mean incubation rate - 6 weeks, ( _.!_) 
a 
Death rate due to HCC/cirrhosis 
Rate at which hepatitis C develops into cirrhosis 
10-14 15+ years 
ears 
280 473 
2,520 3,450 
0 972 
0.14 0.14 
147 
0.182 
1% 
-
0.6 
0.00625 
0.003 
Table 40. Parameters: population 14,700 with high infectivity rates and a low 
probability of infection from a single needle sharing act. 
Like Figure 6. The results here indicate a decline in the total susceptible population, with 
those in the O - 4 years injecting group in most rapid decline and those in the 10-14 years 
injecting group is the slowest. The population of susceptible IDU' s is reduced by 50% 
after 71 months. 
4000 
3500 
! 3000 
~ 2500 !. 
0 2000 
.. 
_8 1500 
E 
~ 1000 1-..r--..._,::--..._ 
500 
0 
Number ofsusceptibles, X(t) 
Number of months 
Total Susceptible 
- 0-4years 
- &-9years 
- 10-14years 
--15+ years 
Figure 12. Number of susceptibles after 20 years, population 14,700, high iofectivity 
rates and a low probability of infection from a single needle sharing act. 
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In this situation, where the higher infectivity rates suggested by Croft (1993) are used, 
after 20 years this IVDU population now numbers I2,200, with 822 not infected, but at 
risk, 8,806 infected and still needle sharing and with 2,572 persons having severe 
cirrhosis or HCC. 
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Figure 13. Number of infectious after 20 years, population 14,700, high infectivity 
rates and a low probability of infection from a single needle sharing act. 
The population of infectious individuals (Figure 13) peaks at 78 months, while the 
number of persons moving into the removals category (Figure 14) doubles after 136 
months. In contrast to the data obtained in 5. I. I, the higher infectivity rates have not 
resulted in higher numbers of those infected only those removed. 
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Figure 14. Number of removals after 20 years, population 14,700, high infectivity 
rates and a low probability of infection from a single needle sharing act. 
Using the same initial population numbers and probability of infection, the table below 
gives results based on recruitment and migration rates of3%, 5% and 7%. 
Recruitment Migration Susceptibles Infectious Removed Total 
Rate Rate X(t) Y(t) A(t) 
3% 3% 2,274 8,833 1,872 12,979 
5% 5% 3,706 8,443 1,366 13,515 
7% 7% 5,095 7,790 997 13,882 
Table 41. Number of susceptible, infectious and removals after 20 years with 
varying recruitment and migration rates. 
These results once again demonstrate a movement into the IVDU population where each 
person is susceptible to infection and a corresponding movement out prior to infection 
with hepatitis C. 
Page 96 
5 .1. 4 Population 14, 700 with high infectivity rates and a high probability of infection 
from a single needle sharing act. 
This section will deal with higher infectivity rates and where the probability of infection 
during a single needle sharing act is 0.686. Initial recruitment and migration rates will be 
set at 1% and the other parameters and population numbers will be unchanged. 
The graphs shown below demonstrate almost no difference in the total numbers in each 
group when compared to section 5 .1.2, despite a difference in the initial population 
numbers for each of susceptible and infectious. This IVDU population now numbers 
12, 116, with 192 not infected, but at risk, 9,289 infected and still needle sharing and with 
2,634 persons having severe cirrhosis or HCC. 
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Figure 15. Number of susceptibles after 20 years, population 14,700, high infectivity 
rates and a high probability of infection from a single needle sharing act. 
Like Figure 9, these results illustrates a rapid decline in the total susceptible population, 
with those in the O - 4 years injecting group in most rapid decline and those in the 10-14 
years injecting group is the slowest. The population of susceptible IDU' s is reduced by 
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50% after only 16 months. The higher probability of infection results in a rapid shift 
from the susceptible group into the infected population. 
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Figure 16. Number of infectious after 20 years, population 14,700, high infectivity 
rates and a high probability of infection from a single needle sharing act. 
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Figure 17. Number of susceptibles after 20 years, population 14,700, high infectivity 
rates and a high probability of infection from a single needle sharing act. 
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577 
S% 963 13,449 
7% 7% 1,348 11,373 1,102 13,823 
-Table 42. Number of susceptible, infectious and removals after 20 years with 
-varying recruitment and migration rates. 
As with the data obtained for recruitment and migration rates of 1%, the results obtained 
with the higher infectivity and 3%, 5% and 7% recruitment and migration almost exactly 
mirror those obtained in 5.1.2. 
'·--· ': --
· .. ·Given these results and the similar trends and close figur~s s~n between section ·5; t' .-_1.-
-.- - and 5.1.3 it would appear there is little effect between the lower and higher populati_On·_ ' ·-
numbers in each group and the duration of use subgroups. 
.• ::."L"-Using the rates of infection supplied by the 1999 HIV/AIDS, Hepatitis C & Sexually •-
~ - -~-~-: :;.-· 
'~"" 
:t-~missible Infections in Australia: Annual Surveillance report population numbers are 
., ---. ,/----
0-4 years 5-9 years 
4,254 1,321 
871 2,940 
0 0 
1% rate, 
Probability of transmission during single needle shtlfin.g••~-~~~~j~/ 
(Rate of nccd.lc sharing*Jlrobability of infection) 
Migration rate out of IVDU population, (!l) 
Mean incubation rate - 6 weeks, ( _..!_) 
a 
Death rate due to HCC/cirrhosis 
probability of infection from a single needle sharing act. 
10-14 15+ years 
ears 
1,157 2,009 
2,576 3,175 
0 1296 
Figure 18 illustrates a decline in the tota1 susceptible population, with those in the 0 - 4 
.. r;, Years injecting group in most rapid decline and those in the 10wl4 years injecting group is 
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Figure 18. Number of susceptibles after 20 years, population 19,600, low infectivity 
rates and a low probability of infection from a single needle sharing act. 
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Figure 19. Number of infectious after 20 years, population 19,600, low infectivity 
rates and a low probability of infection from a single needle sharing act. 
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The population of infectious individuals (Figure 19) peaks at 75 months, while the 
number of persons moving into the removals category (Figure 20) doubles after 124 
months. 
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Figure 20. Number of removals after 20 years, population 19,600, low infectivity 
rates and a low probability of infection from a single needle sharing act. 
In this situation, where the lower infectivity rates are used, after 20 years this IVDU 
population now numbers 16,496, with 1,260 not infected, but at risk, 11,889 infected and 
still needle sharing and with 3,347 persons having severe cirrhosis or HCC. 
Using the same initial population numbers and probability of infection, the table below 
gives results based on recruitment and migration rates of 3%, 5% and 7%. 
Recruitment Migration Susceptibles Infectious Removed Total 
Rate Rate X(t) Y(t) A(t) 
3% 3% 3,232 11,810 2,427 17,467 
5% 5% 5,175 11,198 1,763 18,136 
7% 7% 7,059 10,254 1,280 18,594 
Table 44. Number of susceptible, infectious and removals after 20 years with 
varying recruitment and migration rates. 
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As the recruitment rate increases among this cohort the number of susceptible IDU' s 
increases. The corresponding migration rate show a movement out of the drug using 
population and a smaller number of people suffering ill effects from cirrhosis and 
hepatocellular carcinoma. 
5.2.2 Population 19,600 with low infectivity rates and a high probability of infection 
from a single needle sharing act. 
Consideration will now be given to population number where the probability of infection 
during a single needle sharing act is 0.686. Initial recruitment and migration rates will be 
set at 1 % and the other parameters and population numbers will be unchanged. 
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Figure 21. Number of susceptibles after 20 years, population 19,600, low infectivity 
rates and a high probability of infection from a single needle sharing act. 
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Once again the higher probability of infection results in a rapid shift from the susceptible 
group into the infected population. The population of susceptible individuals decreases 
by 500/o after only 18 months. 
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Figure 22. Number of infectious after 20 years, population 19,600, low infectivity 
rates and a high probability of infection from a single needle sharing act. 
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Figure 23. Number of removals after 20 years, population 19,600, low infectivity 
rates and a high probability of infection from a single needle sharing act. 
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Figure 22 demonstrates a rapid increase in the number of infections individuals, with the 
population peaking after 60 months and then decreasing slightly as they move into the 
removals group. Figure 23 shows a steady increase in the number of removals, with a 
doubling of the population after 112 months. 
Using the same initial population numbers and high probability ofinft:etion from a single 
needle sharing act, the table below gives results based on recruitment and migration rates 
of3%, 5% and 7%. 
Retruitment Migration Susceptibles Infectious Removfd Total 
Rate Rate X(t) Y(t) A t 
3% 3% 820 13,835 2,603 17,257 
5% 5% 1,367 14,652 1,946 17,965 
7% 7% 1,914 15,071 1,468 18,454 
Table 45. Number of susceptible, infectious and removals after 20 yean with 
varying recruitment and migration rates. 
Once more results indicate a raptd increase in the number of IDlJ's that are nc~ infected, 
with a small increase in those with hepatitis C. The corresponding decrease ofthose in 
the removal category indicate that there are a significant number !ea'ling without 
becoming infected with the virus. 
5.2.3 Population 19,600 with high infectivity rates and a low probability ofinfection 
from a single needle sharing act. 
Using the rates of infection supplied by Crofts (1993) population numbers are as follows: 
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0-4 years 5-9 years 
IVDU's that do not have HCV, X(t) 
IVDU's who do have HCV, Y(t) 
IVDU's with cirrhosis/HCC, A(t) 
Rate of needle sharing per month, (n) 
Parameters 
1% recruitment rate, (A) 
3,147 
1,978 
0 
0.15 
1,240 
3,021 
0 
0.14 
Probability of transmission during single needle sharing act (P) 
(Rate of needle sharing*probability of infection) 
Migration rate out ofIVDU population,(µ) 
Mean incubation rate - 6 weeks, ( _!_) 
a 
Death rate due to HCC/cirrhosis 
Rate at which hepatitis C develops into cirrhosis 
10-14 15+ years 
ears 
373 583 
3,360 4,601 
0 1296 
0.14 0.14 
196 
0.182 
1% 
0.6 
0.00625 
0.003 
Table 46. Parameters: Population 19,600 with high infectivity rates and a low 
probability of infection from a single needle sharing act. 
Figure 24 illustrates a decline in the total susceptible population, with those in the O - 4 
years injecting group in most rapid decline and those in the 10-14 years injecting group is 
the slowest. The population of susceptible IDU's is reduced by 50% after 71 months. 
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Figure 24. Number of susceptibles after 20 years, population 19,600, high infectivity 
rates and a low probability of infection from a single needle sharing act. 
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Figure 25. Number of infectious after 20 years, population 19,600, high infectivity 
rates and a low probability of infection from a single needle sharing act. 
The population of infectious individuals (Figure 25) peaks at 78 months, while the 
number of persons moving into the removals category (Figure 26) doubles after 124 
months. 
3900 
3600 
111 3300 
f5 3000 
f 2700 
!. 2'400 
0 2100 
._ 1800 
_! 1500 
E 1200 
:I 900 
z 600 
300 
Number with Cirrhosis/HCC, A(t) Total Refroved 
0 -1--~--.--.--,.--,----.--,-~-r--.--.-.---,-----.--,-...--,-.---.--,-..-. 
Number of months 
Figure 26. Number of removals after 20 years, population 19,600, high infectivity 
rates and a low probability of infection from a single needle sharing act. 
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In this situation, where the higher infectivity rates suggested by Croft (1993) are used, 
after 20 years this lVDU population now numbers 16,285, with 1,094 not infected, but at 
risk, 11,759 infected and still needle sharing and with 3,432 persons having severe 
cirrhosis or HCC. Once again. in contrast to the data obtained in 5.2.1, the higher 
infectivity rates have not resulted in higher numbers of those infected only those 
removed. 
Using the same initial population numbers and probability of infection, the table below 
gives results based on recruitment and migration rates of 3%, 5% and 7%. 
Recruitment Migration Susceptibles Infectious Removed Total 
Rate Rate X(t) Y(t) A(t) 
3% 3% 3,029 11,791 2,498 17,318 
5% 5% 4,937 11,268 1,822 18,028 
7% 7% 6,789 10,396 1,331 18,516 
Table 47. Number of susceptible, infectious and removals after 20 years with 
varying recruitment and migration rates. 
These results once again demonstrate a movement into the IVDU population where each 
person is susceptible to infection and a corresponding movement out prior to infection 
with hepatitis C. 
5.2.4 Population 19600 with high infectivity rates and a high probability of infection 
from a single needle sharing act. 
This section will deal with higher infectivity rates and where the probability of infection 
during a single needle sharing act is 0.686. Initial recruitment and migration rates will be 
set at 1% and the other parameters and population numbers will be unchanged. 
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This IVDU population now numbers 16,176, with 256 not infected, but at risk, 12,407 
infected and still needle sharing and with 3,513 persons having severe cirrhosis or HCC. 
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Figure 27. Number of susceptibles after 20 years, population 19,600, high infectivity 
rates and a high probability of infection from a single needle sharing act. 
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Figure 28. Number of infectious after 20 years, population 19,600, high infectivity 
rates and a high probability of infection from a single needle sharing act. 
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Figure 29. Number of removals after 20 years, popuJation 19,600, high infectivity 
rates and a high probability of infection from a single needle sharing act. 
Once again the higher probability of infection results in a rapid shift from the susceptible 
group (Figure 27) into the infected population. The population of susceptible individuals 
decreases by 50%, after only 18 months. Figure 28 indicates a corresponding shift into 
the infectious group, where the population peaks after 48 months and a doubling of the 
removals group (Figure 29) after 126 months. 
Using the same initial population numbers and probability of infection, the table below 
gives results based on recruitment and migration rates of 3%, 5% and 7%. 
Recruitment Migration Susceptibles Infectious Removed Total 
Rate Rate X(t) Y(t) A(t) 
3% 3% 769 13,848 2,603 17,221 
5% 5% 1,283 14,710 1,947 17,940 
7% 7% 1,797 15,170 1,469 18,436 
Table 48. Number of susceptible, infectious and removals after 20 years with 
varying recruitment and migration rates. 
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As with previous simulations these results indicate a rapid increase in the number of 
IDU's that are susceptible, with a sma11 increase in those with hepatitis C. The 
corresponding decrease of those in the removal category indicate that there are a 
significant number leaving without becoming infected with the virus due to the higher 
migration rate. 
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TREATMENT COSTS 
6.1 Treatment costs from other researck 
Models on the costs and the effects of treatment with aM Interferon have increased in 
frequency in recent years as the efficacy of different treatment protocols are better 
understood. Three such studies examine the Australian situation, one examines treatment 
costs in Britain, while the majority of others originate from the United States of America. 
Sheill et al (1994), used a Markov modelling process to simulate the costs and outcomes 
of a hypothetical cohort of patients with hepatitis C, who were treated both with and 
without a-Interferon. In this model, treatment costs ranged from $33,230 p{;r life-year 
gained in those with cirrhosis at the commencement of treatment and $71,950 per life-
year gained in those with advanced liver disease. Sheill concluded that little was known 
at this time of the long teim impact of a-Interferon on the disease and given the expense 
of the treatment further monitoring should be undertaken as to the cost-effectiveness of 
the treatment regime. 
Dushieko and Roberts ( 1995) undertook a study on the treatment costs with a-Interferon 
associated with chronic hepatitis B and C. Once again a hypothetical cohort of patients 
with hepatitis B or C were either treated with a-Interferon or were part of a control 
group. A transitional probability model was employed, with two rates of progression, 
two mortality rates and discounted and undiscounted costs employed. (Discounting is 
the process where costs and benefits occurring at different points in time are made 
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commensurate with each other). Mortality rates in the treatment group was lower with 
13 to 221ives saved in the hepatitis C group and fewer patients prot,rressed to cirrhosis. 
Discounted costs per year of life saved ranged from £2,142 to £17,128. 
The following treatment assumptions were used for this model. Patients with chronic 
hepatitis C were treated with 3milliunits of a-Interferon three times a week for 26 weeks. 
An initial response rate of 500/o was assumed, with a 50% relapse rate and a final 
response rate of 25%. Patients with chronic hepatitis and without cirrhosis were seen 
twice yearly, where the initial visit included an extensive testing regime including liver 
biopsy. Patients with cirrhosis were seen four times a year and those with 
decompensating (severe) cirrhosis were seen every 2 months. This final group of 
patients were assumed to require at least one hospital admission per year lasting an 
average of seven days. Finally it was assumed that 20% of the decompensating group 
would undergo a liver transplant , with a survival rate of 800/o after 2 years. The model 
projected the natural history of these patients over a 30-year period. 
In an editorial by Koffand Seeff(1995) limitations of this model were raised. Most 
notably, concerns over the author's assumption that natural course of hepatitis C would 
mirror that of hepatitis B was raised, given the lack of published data to that effect. They 
rightly suggest that a series of rates should have been employed in the hepatitis C model. 
The duration of the model was also questioned, given that many acquire the infection in 
adolescence or early adulthood and longer period may have been more appropriate. 
Subsequent models have however, continued to use the thirty year period for their 
models. Finally Koff and Seeff question the a-Interferon response rates employed by 
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Dushieko and Roberts as no meta~analysis treatment triaJs were cited, nor a primary data 
set analysed. They suggest the response rate of 25% was too high and that 5% to 200/o 
was more reasonable. They also suggest that further relapse among these responders 
should be expected at a later time. Despite these reservations the Dushieko model has 
continued to be used as a template for further models. 
From the United State~ Wong et al (1999) concluded that liver biopsy prior to the 
commencement of a~ Interferon treatment increased the costs of managing patients with 
chronic hepatitis C without improvement to health outcomes. HCV RNA testing would 
miss 36% of sustained responders resulting in marginal cost~cffectiveness ratios up to 
US$4,400. Treatment with a-Interferon produced a marginal cost-effectiveness ratio of 
US$12,400 and reached all potential sustained responders. Wong ( 1999), in another 
article, projected a US$400 reduction in lifetime cost of care and a 1.5 year increase in 
life expectancy associated with a-Interferon treatment. Kim et al (2001) identified 
hospital admissions for diagnoses associated with hepatitis C from a national inpatient 
database. For the year 1995, they estimated 26,700 admissions and 2,600 deaths in the 
United States resulting in total cost ofUS$514 million. Highest hospital charges resulted 
from liver transplant and patient death, with the complications of cirrhosis, variceal 
bleeding, ecephalopathy and hepatorenal syndrome adding significantly to costs and risk 
of death. 
Brown and Crofts (1998) used a Markov model to simulate the progress of hepatitis C 
and estimate the direct health care costs of treating intravenous drug users in Australia. 
Once again they use the hypothetical cohort of 1000 patients as they develop and 
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progress through the sequelae of hepatitis Cover time. The cohort were grouped into a 
limited number of disease states and direct medical costs were employed for ambulatory 
visits and hospital admissions over the course of the disease. Costs associated with every 
1000 newly infected hepatitis C patients resulted in $14.32 million dollars in treatment 
over the years as symptoms progress, with a resultant cummulative cost of$0.5 billion 
after 60 years (1994 dollars) as successive cohorts are added to the pool. A total cost of 
$4 billion would be needed if the current estimate of 10,000 new hepatitis C infections 
per yc'lr among IVDU's was to continue. An emphasis was placed on intervention prior 
to infection as a strategy to reduce health costs. 
Sheill Ct al (1999) re-evaluated their economic evaluation of treatment with a-Interferon 
undertaken in I 994. The authors cite charges in clinical practice, cost reductions in the 
production of a-Interferon and extension of the treatment schedule from 6 months to 12 
months as motivators for this evaluation. 
A Markov model was employed to simulate the costs and effects of 6 months and 12 
months treatment as opposed to no treatment. Their hypothetical cohort consisted of 
1000 patients with chronic hepatitis C aged 40 years at the commencement of treatment. 
As part of their re-evaluation they included meta-analyses on the impact of a·lnterferon 
on the natural history of hepatitis C. Cunent treatment regimes now discontinue the usc 
of a.-Interferon if no response is obS<:!rved nfter 12 weeks. Additionally, studies have 
indicated increased benefits oftreatmcnt for a period of 12 months rather 6 months and 
this practice has now been adopted in Australia. The cohort were divided as follows: 
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Percentage Range 
Disease transition probabilities 
From chronic infection to cirrhosis 200/o 10% ~ 30% 
From cirrhosis to advanced liver failure 20% 10% ~ 30% 
From cirrhosis_ ~~-_!J~p_a_t_()~!.l.!:J!I!!"_~cinoma ___ _:lc;4:_:%::_ ______ :_7'.:_Vo::_-=2,_1 'c:V''---
Effectiveness of treatment 
Long term response after 6 months 
Long term response after 12 months 
Discontinue treatment after 12 weeks 
18% 
35% 
14%~24% 
26%-38% 
beca~f lack of ~~ons~-- ·--=---:,-;-=-f2;';6:;'Y<":;o -;---;---;----'J'-'3'-'%"o.:·-'.39'l~Vo,____ 
Table 49. Division into disease stages of the Shein (1999) cohort. 
All subjects with advanced liver failure or hepatocellular carcinoma were assumed to die 
within 2 years of diagnosis. Treatment costs were calculated using the Medical Benefits 
Schedule for 1996 and included medical management of chronic inft.'Ction, treatment 
with in-Interferon for 6 and 12 months, management of compensated cirrhosis, ascites, 
variceal haemorrhage, hepatic encphalopathy, hepatocellular carcinoma and other 
hospitaJ admissions including transplant and tenninal care. Associated costs arc listed 
below. It was assumed that 2% of patients experiencing cirrhosis would undergo a liver 
transplant each year and that 25% of patients would experience at least one episode of 
septicaemia, requiring hospital admission. 
Page Jl6 
Cost (S) Range (S) 
Medical m_!nB~~~-~!':f_s~_'-'!I_I.IJ~-!~J~_!!~-~- ______ _:4,;0"5 ___ .,20,0e.=-.,-6,.00e__ 
Treatment wilh a-Interferon 
6 months' treatment including discontinuing treatment 
12 mQ_n_!~_s:_ trcatm~nt including discontinl!ing _tr~_!l1c~-­
Cirrhosis {,, .... ,V1lh.xi uvL"Tagc L-:,11fJUitr..l rn,,-x,rtmll of pullL'nts hkdy to 
2,800 1,975 - 3,630 
-~s,_,_,J "'so,___-"'3 .,.62()_::_6,~7<>___ 
L"X{nlt.:m:c 1211:h stl!k of Ct!IhosLS) 2,825 1,400 -- 4,200 
Management of compensated cirrhosis 660 330- 990 
Diuretic-sensitive ascites 1,880 940 -- 2,820 
Refractory ascites 13,640 6,820 -- 20,460 
Variceal hncmorrhagc (Year I) 5,850 2,925-8,775 
Hepatic Encephalopathy (Year 1) 6,375 3,190-9,565 
Hepatocellular carcinoma (Year 1) 8,865 4,435 -- I 3,290 
Liver Transplant (Year I) 92,525 46,265- 138,790 
Scpti~10n~--------- 5 300 ____ 21_~~~.95Q __ _ 
Te_~inal (~r~--- 28,400 J~~_l2___:: __ 4_?1_~9Q __ 
Table 50. Cost of rntdical care, per individual, for the Sheill (t 999) cohort. 
6. 2 TreaJment costs in 20 JetU'S time for hepatiti~ C in Western Australia. 
Treatment costs utilised by Shiell ct a] were based on the Medical Benefits Schedule for 
1996. In order to project the costs twenty years from this current work, an inflationary 
rate will be applied to the figures for a period of27 years in order to model the costs 20 
years following the current simulation. The Australian Bureau of Statistics indicates a 
rise in health costs nationally for the twelve months to March 2003 of7.2%, with most 
increases due to a rise in pharmaceutical costs ( 11.8%)_ Additional Consumer Price 
Index informatinn shows an overall percentage change in the Cl,l for Perth ranging from 
1.8% in 1998-99 to 2.8% in 2001-02. Taking a conservative approach, an inflationary 
rate of 1%, 2% and 3% will be applied. 
Pagell7 
Medical managemc~nt of chronic infection 
Treatment with a-Interferon 
6 months' treatment including discontinuing 
treatment 
12 months' treatment including discontinuing 
treatment 
Cirrhosis (\\Cightul uvcrugc- Mmm!crl ~Hfltlrti!lU of 
1996 
Cost($) 
405 
2,800 
5,150 
n'. 
Cost (S) 
530 
3,663 
6,737 
---
2023 
2-;. 3% 
cost __ m Cost (S) 
691 900 
~~------~ 
4,779 6,220 
8,790 11,440 
plllil:nts hlcly tu cxpo.:ncnce U~Ch si/Jlc IJf cmhosi.~) 2,825 3,696 4,822 6,275 
Management of compensated cirrhosis 660 863 1,127 I ,466 
Diurctic~scnsitivc ascites 1,880 2,459 3,209 4,176 
Refractory ascites 13,640 17,844 23,282 30,298 
Variceal haemorrhage (Year I) 5,850 7,653 9, 985 12,995 
Hepatic Encephalopathy (Year I) 6,3 75 8,340 I 0,881 14,161 
llcpatoccllular carcinoma (Year I) 8,865 11,597 15,132 19,692 
Liver Transplant (Year I) 92,525 121,042 157.930 205,525 
~~~~~l_ll~a__ _ _____ ---~-·- ·---~· 5,3~9 _____ . ~_!?}.±_ _____ -~·-Q"!-~! ___ 1_1 773 
TerminaiCare ------~----- 28J40()~_37,_I_53_ 4~,476_~6_3,085 
Table 51. l/ndiscounled medical cosls or hepatic disease in 20 yean, using 
inflationary rates or I%, 2% and 3%. 
If a 3% discount is applied to the figures the costs will then be: 
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1996 2023 
1 "!. 2% 3% 
Cost($) Cost($) Co•t ($) Cost($) 
Medical managem~_!!-~ of chronic infec~ion 405 514 671 873 
Treatment with a.-Interferon 
6 months' treatment including discontinuing 2,800 3,553 4,636 6,033 
treatment 
12 months' treatment including discontinuing 5,150 6,535 8,527 11,096 
treatment 
--- ---·--·---~-------
Cirrhosis (\\ctgh\00 uvL'fllg.: -- <-~imntcd (XO{Xlrtion of 
p~~ticnl~ likely to cxf!L'Iicncc each stub.: of cirrlwsts) 2,825 3,585 4,677 6,087 
Management of compensated cirrhosis 660 838 1,093 1,422 
Diuretic-sensitive ascites 1,880 2,386 3,113 4,051 
Refractory ascites 13,640 17,309 22,583 29,389 
Variceal haemorrhage (Year I) 5,850 7,423 9,686 12,605 
Hepatic Encephalopathy (Year I) 6,375 8,090 10,555 13,736 
Hepatocellular car.::inoma (Year I) 8,865 11,249 14,678 19,101 
Liver Transplant (Year I) 92,525 117,411 153,192 199,359 
Seeticacmia 
--------· 
5,300 6,726 8,775 11,420 
Tenninal Care 28,400 36,039 47,021 61,192 
--------- -----------
Table 52. Discounted medical cost! of hepatic disease in 20 years, using inflationary 
rates of I%, 2% and 3%. 
From the previous chapter, the expected number of people with hepatitis C (Infectious 
group) range from 7,677 to 11,381 for an initial population of14,700 and 10,254 to 
J 5,170 where the initial population is 19,600. Among this group most will require 
baseline treatment for hepatitis C, and 20% will have developed cirrhosis and will 
required additional care. This cohort will be given a.-Interferon as a treatment regime, 
25% of all those with cirrhosis will have one hospital admission for septicaemia and 2% 
will undergo a liver transplant. 
The number of people (removals group) suffering severe symptoms and requiring 
terminal care range from 958 to 2,634 where the initial population is 14,700 and 1,280 to 
3,513 for an initial population of 19,600. These patients will all require terminal care and 
it is assumed that this group will also require one admission for either management of 
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compensated cirrhosis, ascites, variceal haemorrhage, hepatic encphalopathy, 
hepatocellular carcinoma or septicaemia. 
The proportion of people for each treatment and diagnostic/disease category are given in 
the table below. 
Initial population 14,700 19,600 
Best Case Worst Case Best Case Worst Case 
Infectious 7,677 11,381 10,254 
a.-Interferon Therag~ 
26% discontinue after 12 weeks 1,996 2,959 2,666 
18% long tenn response after 6 months 1,382 2,049 1,846 
35% long tenn response after 12 months 2,687 3,983 3,589 
No resQonsc 4 990 7 398 6 665 
20% of non-responders develop 998 1,480 1,333 
cirrhosis 
25% admission for septicaemia 250 370 333 
2% liver transQlant 20 30 27 
Severe cirrhosis and IICC 958 2,634 1,280 
l4%with HCC 134 369 179 
Table 53. Division into disease stages for best and wont case scenario from 
simulation. 
An overall cost of a 12-week course is not given. In this simulation the number of 
15,170 
3,944 
2,731 
5,310 
9 861 
1,972 
493 
39 
3,513 
492 
patients receiving a-Interferon are charged at halfthe cost of those receiving a six-month 
course. Among those people with severe cirrhosis and expecting to have one hospital 
admission, a range is calculated from the least to the most costly options, not including 
management of HCC or liver transplant. 
The table below shows predicted costs for the best case scenario (that is the lowest 
numbers in the infectious and removal groups) where the initial population is 14.700 
persons. It includes non discounted and discounted rates. Total treatment costs for this 
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cohort range from $74,396,230 for the discounted group with only a 1% average rise in 
the CPI to $151,643,043 undisr..ounted and with an average rise in the CPI of3%. 
Number t•/o CPI lo/e CPI 3%CPI 
or increase increase increase 
rsons 
Undisc:ounted Costs 
Basic management for 7,677 $4,067,436 $5,307,026 $6,906,398 
HCV 
26% discontinue after 1,996 $3,655,659 $4,769,724 $6,207,170 
12 weeks 
18% long term response 1,382 $5,061,732 $6,604,299 $8,594,629 
after 6 months 
35% long term response 2,687 $18,102,723 $23,619,541 $30,737,736 
after 12 months 
20% of non-responders 998 $3,688,336 $4,812,359 $6,262,654 
develop cirrhosis 
25% admission for 250 $1,729,927 $2,257,124 $2,937,351 
septicaemia 
2% liver transplant 20 $2,416,023 $3,152,308 $4,102,315 
Severe cirrhosis and 958 $827,154- $1,079,230- $1,404,477-
HCC- I admission $17,094,522 $22,304,090 $29,025,850 
14% with HCC 134 $1,555,426 $2,029,443 $2,641,054 
Terminal care $35 592,701 $46439 602 $60 435 054 
Total Costs $76,697,145- $100,070,702- $130,228,902-
$89,308,854 $116,525,791 $151,643,043 
3% Disc:ounted Costs 
Basic management for 7,677 $3,945,440 $5,147,815 $6,699,207 
HCV 
26% discontinue after 1,996 $3,545,899 $4,626,632 $6,020,955 
12 weeks 
1 8% long tcnn response 1,382 $4,909,880 $6,406,170 $8,336,790 
after 6 months 
35% long term response 2,687 $17,559,641 $22,910,955 $29,815,604 
after I 2 months 
20% of non-responders 998 $3,577,686 $4,667,988 $6,074,774 
develop cirrhosis 
25% admission for 250 $1,678,030 $2,189,410 $2,849,230 
septicaemia 
2% liver transplant 20 $2,343,542 $3,057,739 $3,979,246 
Severe cirrhosis and 958 $802,340- $1,046,853- $1,362,342-
HCC- 1 admission $16,581,687 $21,634,968 $28,155,074 
14%with HCC 134 $1,508,763 $1,968,560 $2,561,823 
Terminal care $34 524,920 $45,046,414 $58,622,003 
Total Costs $74,396,230 - $97,068,535- $126,321,974-
$86,629,588 Sll3,030,01R $147,093,752 
Table 54. Costs for medical care for best case scenario for population 14,700. 
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Number 1o/e CPI lo/o CPI 3%CPI 
of increase increase increase 
rsons 
Undiscounted Costs 
Basic management for HCV 11,381 $6,029,934 $7,867,560 $10,238,599 
26% discontinue after 12 2,959 $5,419,496 $7,071,091 $9,202,098 
weeks 
18% long term response after 2,049 $7,503,918 $9,790,747 $12,741,367 
6 months 
35% long term response after 3,983 $26,836,927 $35,015,500 $45,568,084 
12 months 
20% of non~rcspondcrs 1,480 $5,467,884 $7,134,226 $9,284,260 
develop cirrhosis 
25% admission for 370 $2,564,583 $3,346,141 $4,354,564 
septicaemia 
2% liver transplant 30 $3,581,706 $4,673,234 $6,081,601 
Severe cirrhosis and HCC- 1 2,634 $2,274,243 - $2,967,320- $3,861,578 -
admission $46,804,731 $61,324,608 $79,805,938 
l4%withHCC 369 $4,276,610 $5,579,910 $7,261,521 
Terminal care $97,861,350 $127 684,667 $166 164 857 
Total Costs $161,816,651 ~ $211,130,391 - $274,758,529 -
$101,123,927 $262,416,588 $341!500,791 
3% Discounted Costs 
Basic management for HCV 11,381 $5,849,036 $7,631,534 $9,931,441 
26% discontinue after 12 2,959 $5,256,911 $6,858,959 $8,926,035 
weeks 
18% long term response after 2,049 $7,278,800 $9,497,020 $12,359,126 
6 months 
35% long term response after 3,983 $26,031,819 $33,965,035 $44,201,041 
12 months 
20% of non~rcspondcrs 1,480 $5,303,848 $6,920,199 $9,005,732 
develop cirrhosis 
25% admission for 370 $2,487,645 $3,245,757 $4,223,927 
septicaemia 
2% liver transplant 30 $3,474,255 $4,533,037 $5,899,153 
Severe cirrhosis and HCC- 1 2,634 $2,206,0 I 5 - $2,878,300 - $3,745,730-
admission $45,590,984 $59,484,869 $77,411,760 
14%with HCC 369 $4,148,312 $5,412,513 $7,043,676 
Terminal care $94 925,510 $123 854 127 $161,179 91 I 
Total Costs $156,962,151 ~ $204,796,480 ~ $266,515,773-
$195,090,209 $254,544,090 $331,255,767 
Table 55. Costs for medical care for worst case scenario for population 14,700. 
In the worst case scenario where the initial population is 14,700 persons total treatment 
costs for this cohort range from $156,962,151 for the discounted group with only a 1% 
average rise in the CPI to $341,500,791 undiscounted and with an average rise in the CPI 
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of3%. This large increase in cost is due to the higher number of people in the cohort 
with severe cirrhosis and HCC, requiring much more extensive treatments. 
Number 1%CPI 2%CPI 3%CPI 
of increase increase increase 
rsons 
Undiscounted Costs 
Basic management for HCV 10,254 $5,432,821 $7,088,478 $9,224,724 
26% discontinue after 12 2,666 $4,882,759 $6,370,783 $8,290,739 
week!; 
18% long tcnn response after 1,846 $6,760,844 $8,821,217 $!!,479,657 
6 months 
35% long tcnn response after 3,589 $24,179,409 $31,548,!01 $41,055,718 
12 months 
20% of non-responders 1,333 $4,926,429 $6,427,762 $8,364,889 
develop cirrhosis 
25% admission for 333 $2,3!0,626 $3,014,791 $3,923,355 
septicaemia 
2% liver transplant 27 $3,227,029 $4,210,468 $5,479,372 
Severe cirrhosis and HCC~ 1 1,280 $1,!05,175- $1,441,978- $1,876,545-
admission $22,840,280 $29,800,872 $38,781,929 
14%withHCC 179 $2,078,231 $2,7!!,574 $3,528,757 
T ennina1 care $47,556,009 $62,048 737 $80,748 298 
Total Costs $102,459,332 - $133,683,887 - $173,972,056 -
SII9JII,679 $155,671,999 $202,586,701 
3% Discounted Costs 
Basic management for HCV 10,254 $5,269,837 $6,875,823 $8,947,983 
26% discontinue after 12 2,666 $4,736,276 $6,179,660 $8,042,017 
weeks 
18% long term response after 1,846 $6,558,019 $8,556,580 $!!,!35,267 
6 months 
35% long term response after 3,589 $23,454,027 $30,601,658 $39,824,047 
12 months 
20% of non-responders 1,333 $4,778,636 $6,234,929 $8,!!3,942 
develop cirrhosis 
25% admission for 333 $2,241,307 $2,924,347 $3,805,654 
septicaemia 
2% liver transplant 27 $3,!30,218 $4,084,154 $5,314,991 
Severe cirrhosis and HCC- 1 1,280 $1,072,020- $1,398,718- $1,820,249-
admission $22,155,072 $28,906,846 $37,618,471 
14%withHCC 179 $2,015,884 $2,630,226 $3,422,895 
T cnninal care $46 129,329 $60 187,275 $78 325 849 
Total Costs $99,385,552 - $129,673,371 - $168,752,894-
$115,732,328 $151,001,839 $196,509,100 
Table 56. Costs for medical care for best case scenario for population 19,600. 
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The table above shows predicted costs for the best case scenario where the initial 
population is 19,600 persons. Total treatment costs for this cohort range from 
$99,385,552 for the discounted group with only a 1% average rise in the CPI to 
$202,586,701 undiscounted and with an average rise in the CPI of3%. 
Number 1%CPI 2%CPI Jo/o CPI 
of increase increase increase 
rsons 
Undiscouoted Costs 
Basic management for HCV 15,170 $8,037,439 $10,486,854 $13,647,266 
26% discontinue after 12 3,944 $7,223,406 $9,424,744 $12,265,069 
weeks 
18% long term response after 2,731 $10,002,146 $13,050,308 $16.983,265 
6 mouths 
35% long term response after 5,310 $35,771,565 $46,672,976 $60,738,760 
12 months 
20% of non-responders 1,972 $7,288,270 $9,509,376 $12,375,206 
dewlap cirrhosis 
25% admission for 493 $3,418,392 $4,460,150 $5,804,300 
sC'pticacmia 
2% liver transplant 39 $4,774,140 $6,229,062 $8,106,308 
Severe cirrhosis and HCC~ 1 3,513 $3,033,187- $3,957,553- $5,150,236-
admission $62,685,863 $81,789,426 $106,438,216 
14%with HCC 492 $5,703,770 $7,441,998 $9,684,7S5 
Terminal care $130 518,953 $170,294,698 $221 616,227 
Total Costs $215,771,270 - $281,527,720- $366,371,424-
$268,200,540 $349,934,848 $455,:394,334 
3% Discounted Costs 
Basic management for HCV 15,170 $7,796,316 $10,172,249 $13,237,8v48 
26% discontinue after 12 3,944 $7,006,704 $9,142,002 $11,897,117 
weeks 
IS% long term response after 2,731 $9,702,082 $12,658,799 $16,473,767 
6 months 
35% long term response after 5,310 $34,698,418 $45,272,787 $58,916,597 
12 months 
20% of non-responders 1,972 $7,069,622 $9,224,095 $12,003,950 
develop cirrhosis 
25% admission for 493 $3,315,841 $4,326,345 $5,630,171 
septicaemia 
2% liver transplant 39 $4,630,915 $6,042,190 $7,863,119 
Severe cirrhosis and HCC~ 1 3,513 $2,942,191 - $3,838,826- $4,995,729-
admission $60,805,288 $79,335,743 $103,245,070 
14%withHCC 492 $5,532,657 $7,218,738 $9,394,242 
Terminal care $126,603,385 $165,185,857 $214 967,740 
Total Costs $209,298,132 - $273,081,888- $355,380,281 -
$260,154,524 $339,436,803 $441,732,504 
Table 57. Costs for medical care for worst case scenario for population 19,600. 
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In the worst case scenario where the initial population is 19,600 persons total treatment 
costs for this cohort range from $209,298,132 for the discounted group with only a I% 
average rise in the CPI to $455,394,334 undiscounted and with an average rise in the CPI 
of3%. 
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CONCLUSION 
This study has focused on developing a model to simulate the transmission of hepatitis C 
among a cohort of intravenous drug users in Perth, Western Australia. In addition. the 
study has examined the potential costs that may arise in treating these infected persons, 
both with a-Interferon and other treatments involving hospital admissions. 
Using two cohorts sires representing variations in the intravenous drug using 
community in Perth, two different probability of infection rates and varying recruitment 
and migration rates for this population, predicted numbers of persons either with the 
virus or suffering severe symptoms, are sufficiently large to cause health planners and 
funding sources concern. 
Among the smaller starting cohort of 14,700 IVDU's the best case scenario is one where 
7,677 people are infected with the virus and will require normal management and 
treatment with a-Interferon, and 958 people will be experiencing severe cirrhosis or 
hepatocellular carcinoma and will require expensive treatment and palliative care 
measures. Among this group the worst case scenario is one where 11,381 persons are 
infected with the virus and 2,634 are severely ill. 
Examining the larger group (n = 19,600), the best scenario resulted in 10,254 persons 
infected with hepatitis C with 1,280 terminally ill and the worst case involves 15,170 
persons infected and 3,513 with severe cirrhosis or hepatocellular carcinoma. 
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Treatment cost for this cohort are predicted to be large. In the best instance costs would 
range from $74,396,230 to $86,629,588, while the predicted costs associated with the 
worst case scenario range from $366,371,424 to $455,394,334. 
The mathematical model illustrates the effectiveness of intervention programs, where the 
number of infected persons decreased when the force of infection was low and the 
migration rate was increased. This phenomenon was not observed with the higher force 
of infection, although in both instances the number of severely ill persons, those that 
require the largest share of the treatment budget, decreased. This has obvious and rather 
urgent implications for those formulating health policy in regard to intervention 
programs. Some of these intervention programs are discussed below. 
Australia has led the world with its innovative programs of harm minimisation that arose 
following the advent of IDV I AIDS. Among these programs included needle exchange 
programs and the availability ofFitpacks. In Western Australia, the only really safe 
needle program is the Fitpack and these must be bought at the local pharmacy. This 
process of having to purchase injecting equipment marginalises many IDU's, especially 
new initiates, leaving them more prone to needle sharing. 
Western Australia has a well developed network of medical professionals involved in 
intervention programs such as Methadone substitution. There is also a program run by a 
medical practitioner involving rapid detoxification and the implantation ofNaltrexone. 
This program, while receiving government funding it is yet to be accepted as an 
approved intervention program as it has not undergone stringent clinical trails. The 
Page 127 
waiting list for both programs are large, indicating a desire by many IDU's to change 
their current lifestyles. 
Increased funding for these treatment programs would dramatically decrease the number 
of people in both the susceptible and infectious cohorts, lowering the number who 
become infected and decreasing the risk ofsusceptibles sharing injecting equipment with 
those who are infected. Involvement in a treatment program with readily available 
medical intervention would also lead to earlier detection of those with the virus, 
dramatically improving their chances of a sustained response to a~lntcrferon. This 
resultant lowering of the number of persons infected with the virus would have a huge 
impact on future health budgets. 
Education programs aimed at young adolescents are also desirable. Brochures that 
suggest ways to avoid hepatitis C infection are included in the Fitpacks, but many novice 
IDU's are not confident to purchase this equipment and are more likely to be sharing. 
While many may be aware of the dangers ofHIV/AIDS, fewer are aware of the 
associated risks of sharing needles and injecting equipment with infection with hepatitis 
c. 
7.1. Limitations and pos.''iible improvement~ to the mathematical model. 
No discernable differences were noted between the two different proportions ofHCV 
infection as cited by the 1999 HlV/AIDS, Hepatitis C & Sexually Transmissible 
Infections in Australia and those given by Crofts (1993). In all simulations the difference 
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between both sets of data were negligible and in the case of the smaller population cohort 
at the highest force of infection, almost identical. 
Further refinements to the mathematical model might include one that more accurately 
portrays the growth of the intravenous drug using population in relation to predicted 
population growths within Western Australia. The current model is dependent only on 
growth in relation to migration and recruitment rates and these recruitment rates may be 
better served to also reflect growth in accordance with the growth of the overall 
population. 
Further adjustments to the model could be made via the migration rates. This simulation 
sets both recruitment and migration rates as equal. Further investigation into these 
migration rates, from sources such as the number entering and completing treatment 
programs per year, the average length of time involved in intravenous drug use prior to 
seeking intervention and the number of fatal overdoses would serve to further refine the 
migration rate. 
It is not inconceivable that with the development of gene technology, a vaccine may be 
available, at least for the more common types of hepatitis C, within the twenty~year time 
frame examine in this study. Art analysis of the effects on treatment costs compared with 
vaccination costs for such a vaccine, especially one administered to all young 
adolescents, would be of interest. 
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Finally, establishing a model that examined differences among males and females would 
assist in establishing more precise results. Literature suggests lower infection rates for 
females than males, most likely due to a more stringent adherence to not sharing needles. 
The examination of the treatment cost were based on costings already undenakcn by a 
leading Australian researcher (Shcill et al, 1999). The treatment costs have been applied 
to the predicted number of persons in each category as suggested by the model, rather 
than on a hypothetical group of 1000 intravenous dn1g users. The prr.:dictcd treatment 
costs arc in line with other published data, most notable Brown and Croft ( 1998), given 
that Western Australia has one-tenth of the national population and presumably one-tenth 
of the intravenous drug using population. 
A further addition to this estimation may be to develop a Markov model similar to that 
developed by Sheill et al, and to apply the predicted number of persons in each category 
from the simulation and undertake a cost benefits analysis of a-Interferon treatment 
regimes. 
This study has developed a model that will predict future numbers of persons suffering 
from hepatitis C and the resultant treatment costs that will be incurred. Unless 
immediate and comprehensive intervention and education programs arc instituted, health 
officials and medical institutions will be faced with an epidemic of persons with hepatitis 
C and its associated complications. As with all things, money that is wisely invested in 
prevention today will impact significantly on the quality of life and available resources in 
future years. 
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